


























exert	 a	 wide	 range	 of	 physiological	 effects	 via	 production	 and	 secretion	 of	 hormones	 in	
response	 to	 ingested	 nutrients,	 bacterial	 metabolites	 and	 systemic	 signals.	 Glucagon-like	
peptide-1	(GLP-1)	is	one	such	hormone	secreted	from	so-called	L-cells	found	in	both	the	small	







murine	 small	 intestinal	 organoids	was	 established	 as	 an	 in	 vitro	model.	 This	was	 used	 to	




Roughly	half	of	 colonic,	but	not	 small	 intestinal,	 L-cells	 co-produce	 the	orexigenic	peptide	
insulin-like	 peptide	 5	 (INSL5).	 This	 hitherto	 poorly	 examined	 subpopulation	 of	 L-cells	was	
characterised	 through	 transcriptomic	 analysis,	 intracellular	 calcium	 imaging	 (using	a	novel	
GCaMP6F-based	 transgenic	 mouse	 model),	 LC/MS	 peptide	 quantification	 and	 3D	 super	
resolution	microscopy	(3D-SIM).	Based	on	the	observed	prevalent	co-storage	of	GLP-1,	PYY	
and	INSL5	in	secretory	vesicles	and	similar	secretory	responses	of	both	hormones	to	a	range	





was	performed	on	 cells	 isolated	 from	mice	with	 a	pan-EEC	 fluorescent	marker	 (NeuroD1-
Cre:Rosa26-EYFP).	 This	 illustrated	 that	 INSL5-producing	 L-cells	 form	 one	 of	 two	
	 II	
transcriptomically	 distinct	 subpopulations	 of	 L-cells	 in	 the	 murine	 colon,	 with	 the	 other	
distinguished	 by	 expression	 of	 neurotensin	 (Nts).	 Another	 major	 EEC	 subpopulation,	
enterochromaffin	 (EC)	 cells	 could	 be	 split	 into	 three	 groups,	 mechanosensitive	 and	 pro-
inflammatory	EC	cells	distinguished	respectively	by	Piezo2	and	Tac1	expression	and	a	third	
Sct-expressing	group.	 Immunofluorescent	 labelling	and	RT-qPCR	analysis	 revealed	that	 the	
Nts-expressing	and	Insl5-expressing	L-cell	subpopulations	are	proximally	and	distally	enriched	




In	 summary,	 the	 work	 presented	 suggests	 that	 different	 L-cell	 subpopulations	 exist	 that	







































































































































































































































































































































































































































Obesity	 is	 characterised	 by	 abnormally	 high	 levels	 of	 adipose	 deposition	 whilst	 type	 2	
diabetes	 is	 characterised	 by	 insulin	 resistance	 and	 pancreatic	 beta	 cell	 dysfunction	 [5,6].	
Under	 normal	 physiological	 conditions,	 post-prandial	 insulin	 secretion	 from	 beta-cells	
counteracts	the	increase	in	glycaemia	seen	following	glucose	absorption	from	a	meal.	This	is	
achieved	by	 a	 combination	of	 insulin-stimulated	 glucose	uptake	by	peripheral	 tissues	 and	
glycogen	 synthesis	 in	 the	 liver	 [7].	 Insulin	 resistance	 in	 type	 2	 diabetes	 attenuates	 the	












are	 available	 for	 obesity.	 Unfortunately,	 some	 of	 these	 weight	 loss	 treatments,	 such	 as	
rimonabant,	amphetamine	derivatives	and	sibutramine	have	been	withdrawn	from	sale	due	













prescribed	 for	 weight-loss	 due	 to	 their	 ability	 to	 suppress	 appetite.	 Pharmacologically,	
amphetamine	mediates	competitive	inhibition	of	monoamine	reuptake	and	displacement	of	
monoamines	sequestered	into	secretory	vesicles,	increasing	monoaminergic	(dopaminergic,	
serotonergic	 and	 noradrenergic)	 neurotransmission	 [17].	 This	 increased	 monoaminergic	
neurotransmission	 can	 reduce	 food	 intake.	 Enhancement	 of	 dopaminergic	
neurotransmission,	for	example,	can	reduce	appetite	by	increasing	hypothalamic	expression	
of	 the	 anorexigenic	 neuropeptide	 cocaine	 and	 amphetamine	 regulated	 transcript	 (CART)	
whilst	decreasing	expression	of	the	orexigenic	neuropeptide	Y	(NPY)	[18].	Although	effective	









expenditure	whilst	 suppressing	appetite	 [19].	Unfortunately,	 sibutramine	has	 largely	been	
withdrawn	from	clinical	use	including	in	the	Europe	and	USA	due	to	association	with	increased	









producing	 the	 appetite	 stimulating	 neuropeptide	 orexin	 and	 attenuated	 expression	 of	
anorexigenic	neuropeptides	such	as	corticotropin-releasing	hormone	(CRH)	[21].	Conversely,	
inverse	agonism	of	CB1	by	 rimonabant	mediates	an	anorexigenic	effect	 that	 likely	 reflects	
increased	 activity	 of	 neurons	 producing	 anorexigenic	 over	 orexigenic	 neuropeptides.	




A	 more	 recently	 approved	 drug	 treatment	 is	 combined	 administration	 of	
naltrexone/bupropion.	 Bupropion	 is	 an	 antidepressant	 that	 boosts	 noradrenergic	 and	
dopaminergic	 neurotransmission	 by	 blocking	 reuptake	 of	 noradrenaline	 and	 dopamine	










derive	 from	 simulation	 of	 anorexigenic	 POMC	 neurons	 within	 the	 arcuate	 nucleus	 [24].	
Preferential	activation	of	5-HT2C	receptors	over	5-HT2B	receptors	by	lorcaserin	avoids	known	
cardiovascular	 issues	 associated	 with	 5-HT2B	 receptor	 activation	 [25].	 Such	 issues	 have	










maintain	 a	 therapeutic	dose,	 liraglutide	must	be	 injected	once/twice	daily.	 Recent	 clinical	
trials	have	focussed	on	the	potential	of	incretin	mimetics	with	longer	biological	half-lives	(and	
therefore	longer	lasting),	such	as	semaglutide,	which	could	be	administered	once	a	week	for	










In	 common	with	 obesity,	 type	 2	 diabetes	 can	 be	 partly	managed	 by	 dietary	 and	 lifestyle	








tissues	 to	 insulin	 and	 promotion	 of	 beta-cell	 function.	 Activation	 of	 adenosine	
monophosphate-activated	protein	kinase	(AMPK)	appears	key	to	the	effects	of	metformin	on	





Insulin	 and	 its	 analogues	 are	 the	 traditional	 first	 line	 treatment	 for	 type	 1	 diabetes,	
compensating	for	the	loss	of	endogenous	insulin	resulting	from	autoimmune	induced	beta-
cell	 death.	 In	 contrast,	 most	 type	 2	 diabetics	 produce	 endogenous	 insulin	 on	 an	 insulin	
resistant	 background.	 The	 production	 of	 endogenous	 insulin	makes	 therapeutic	 dosing	 of	
insulin	 analogues	 more	 complex	 for	 type	 2	 than	 type	 1	 diabetes.	 Subsequently,	 insulin	
analogues	tend	to	be	utilised	10-15	years	after	 initial	diagnosis,	 following	behavioural	and	
other	 pharmacological	 interventions	 [35].	 Furthermore,	 patient	 compliance	 to	 insulin	
treatment	 is	 lower	 than	 for	 orally	 administrable	 drugs	 since	 insulin	 injections	 cause	
discomfort	and	potentially	life-threatening	episodes	of	hypoglycaemia	[36].	Recent	advances	
in	 the	closed-loop	 insulin	pump,	also	known	as	 the	 ‘artificial	pancreas’,	may	help	alleviate	
dosing	issues.	This	system	constantly	monitors	glycaemic	levels	and	adjusts	the	administered	
dose	of	insulin	accordingly	avoiding	the	need	for	regular	self-administered	insulin	injections	
[37].	 This	 system	 was	 initially	 designed	 for	 treatment	 of	 type	 1	 diabetes,	 but	 by	 using	
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Sulphonylureas	 (such	 as	 glimepiride)	 and	 glinides	 (such	 as	 nateglinide)	 restore	
normoglycaemia	 in	 type	 2	 diabetic	 patients	 through	 stimulation	 of	 endogenous	 insulin	
secretion	 from	 pancreatic	 beta-cells.	 Stimulation	 of	 insulin	 secretion	 by	 these	
pharmacological	 agents	 results	 from	 inhibition	 of	 beta-cell	 ATP-sensitive	 potassium	 (KATP)	
channels	causing	plasma	membrane	depolarisation	and	increased	insulin	exocytosis	[39,40].	
Although	 effective	 insulin	 secretagogues,	 sulphonylureas	 (in	 common	 with	 insulin	
administration)	 can	 trigger	 a	 dangerous	 state	 of	 abnormally	 low	 glycaemia	 known	 as	
hypoglycaemia	[6].	More	recent	drug	development	efforts	in	the	diabetes	field	have	focussed	




Newer	anti-diabetes	drugs	 include	 incretin	mimetics,	such	as	exenatide,	which	 imitate	the	
actions	of	the	gut	peptide	glucagon-like	peptide	1	(GLP-1)	to	restore	normoglycaemia	through	
the	 incretin	 effect.	 The	 incretin	 effect	 accounts	 for	 the	 higher	 levels	 of	 insulin	 secretion	
elicited	by	oral	compared	with	intravenous	administration	of	glucose	under	similar	glycaemic	
conditions.	 It	 is	exerted	by	 the	 incretin	peptides	GLP-1	and	glucose	 insulinotropic	peptide	
(GIP)	secreted	from	endocrine	cells	of	the	intestinal	epithelium	known	as	enteroendocrine	
cells	 (EECs).	 GLP-1	 and	 GIP	 can	 act	 directly	 on	 pancreatic	 islets	 to	 stimulate	 endogenous	
insulin	 secretion	 from	beta	cells	and	modulate	glucagon	secretion	 from	alpha	cells	 (GLP-1	








therapeutic	 benefits.	 	 Gliptins	 represent	 a	 licensed	 class	 of	 such	 DPP-4	 inhibitors.	 Unlike	
incretin	mimetics,	gliptins	can	be	orally	administered.	However,	incretin	mimetics	are	more	








































RYGB	 can	 additionally	 be	 used	 to	 treat	 type	 2	 diabetes	which	 can	 lead	 to	 remission	with	
Purnell	et	al.	finding	that	68.7%	of	patients	studied	were	in	remission	3	years	post-RYGB	[49].	





insulin	 secretion	 acting	 to	 restore	 normoglycaemia	 and	 exerting	 satiety.	 Conversely,	 the	
foregut	 hypothesis	 suggests	 that	 bypassing	 the	 early	 small	 intestine	 reduces	 secretion	 of	




directly	 to	 the	 distal	 small	 intestine	 which	 is	 enriched	 in	 proglucagon-expressing	 EECs	
enhancing	 GLP-1	 and	 PYY	 (another	 hormone	 co-secreted	 with	 GLP-1)	 secretion	 with	
consequential	 effects	 on	 postprandial	 insulin	 secretion	 and	 satiety	 [53].	 Investigating	 the	
nutrient	 sensing	 mechanisms	 of	 proglucagon-expressing	 EECs	 in	 particular,	 which	 is	 the	
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1.5. Targeting	 the	 enteroendocrine	 system	 –	 a	 novel	 therapeutic	
approach	
Pharmacological	targeting	of	enteroendocrine	cells	may	achieve	therapeutic	benefit	through	
modulated	 secretion	 of	 endogenous	 gut	 hormones.	 Such	 an	 approach	might	 achieve	 the	
aforementioned	 clinical	 benefits	 of	 RYGB	 by	 stimulating	 the	 release	 of	 incretins	 or	




























physiological	effects	both	 in	a	 local	paracrine	 fashion	and	at	distant	 sites	via	 the	systemic	
circulation.	One	key	characteristic	of	EECs	is	the	ability	to	chemosense	luminal	contents	of	
the	 gastrointestinal	 tract,	 neurotransmitters	 and	 systemic	 factors	 and	modulate	 secretory	
activity	 accordingly.	 Many	 EECs,	 for	 example,	 respond	 to	 dietary	 stimuli	 such	 as	
carbohydrates,	peptides	and	lipids	regulating	satiety,	glycaemia	and	gastrointestinal	motility	
[52,55].	EEC	chemosensory	 responses	are	 largely	 regulated	by	G-protein	coupled	 receptor	
(GPCR)	signalling	and	more	specifically	the	Gq,	Gs	and	Gi	signalling	pathways	which	modulate	
exocytosis	 through	the	secondary	messengers	 IP3,	DAG	and	cAMP	(figure	1)	 [55].	Example	
modulations	 include	 changes	 to	 intracellular	 calcium	 (Ca2+)	 levels	 (critical	 to	 exocytosis)	
directly	 through	 IP3-dependent	 release	 of	 intracellular	 Ca2+	 stores	 and	 indirectly	 by	
modulating	the	activities	of	voltage-gated	calcium	channels	through	which	Ca2+	influx	occurs	





sodium-dependent	 active	 transport	 of	 glucose	 and	 accordingly	 depolarises	 the	 plasma	
membrane	triggering	GLP-1	secretion	[59].	Likewise,	the	potent	GLP-1	secretion	triggered	by	














Figure	 1:	 Schematic	 illustrating	 the	 Gq,	 Gs	 and	 Gi	 signalling	 pathways	 underlying	
chemosensation	 in	 enteroendocrine	 cells.	 Stimulation	 of	 the	 Gq	 pathway	 stimulates	
phospholipase	C	(PLC)	activity	which	catalyses	PIP2	hydrolysis	to	the	secondary	messengers	IP3	





















Historically	 the	 EECs	were	 thought	 to	 produce	 one	 particular	 gut	 hormone	 and	 split	 into	
subtypes	according	to	which	gut	hormone	they	produced.	However,	this	canonical	view	has	
been	challenged	by	transcriptomic	and	immunohistological	studies	indicating	a	large	degree	
of	 overlap	 in	 the	 gut	 hormone	 profiles	 produced	 and	 secreted	 by	 the	 historical	 EEC	
subdivisions	 [62–65].	 In	 light	 of	 these	 findings	 Fothergill	 and	 Furness	 propose	 that	 a	 new	
classification	system	is	required	for	EECs	[66].	For	simplicity,	in	this	thesis	the	classical	terms	
























Proglucagon-expressing	 cells,	 referred	 to	 henceforth	 as	 ‘L-cells’	 (a	 classical	 term	 for	
proglucagon-expressing	cells	of	the	gastrointestinal	tract),	are	localised	to	the	epithelium	of	
the	small	and	large	intestines	and	secrete	a	range	of	proglucagon	derived	peptides	(peptides	
derived	 from	post-translational	processing	of	 the	proglucagon	precursor	polypeptide)	 into	
the	circulation	(see	figures	2	and	3)	[67,68].	Proglucagon	and	its	derivatives	are	produced	in	
alpha-cells	 of	 the	 pancreas,	 a	 subset	 of	 central	 neurons	 and	 intestinal	 L-cells.	 Whilst	
pancreatic	alpha-cells	produce	glucagon	and	glicentin-related	pancreatic	polypeptide	(GRPP)	
from	 proglucagon,	 L-cells	 do	 not.	 Conversely,	 L-cells	 produce	 GLP-1,	 GLP-2,	 glicentin	 and	
oxyntomodulin	 which	 are	 not	 produced	 by	 alpha-cells.	 These	 differences	 in	 proglucagon	
processing	derive	 from	differential	expression	of	different	prohormone	convertases	 (Pcsk)	
that	cleave	at	different	 sites	along	 the	proglucagon	polypeptide	chain.	Alpha-cells	express	
Pcsk2	 which	 favours	 glucagon	 and	 GRPP	 production	 whilst	 L-cells	 express	 Pcsk1/3	 which	
favours	GLP-1,	GLP-2,	glicentin	and	oxyntomodulin	production	[69].	
	
Secretion	of	GLP-1	 from	L-cells	 is	 triggered	by	a	range	of	nutrients	digested	and	absorbed	







suppression	 of	 glucagon	 secretion	 from	 alpha-cells	 may	 result	 indirectly	 from	 GLP-1	
stimulated	 somatostatin	 secretion	 from	 delta-cells	 mediating	 paracrine	 inhibition	 [76].	
Regarding	the	anorexigenic	effects	of	GLP-1,	these	effects	can	be	mediated	by	activation	of	
GLP1R	 on	 peripheral	 vagal	 afferents	 innervating	 the	 gastrointestinal	 tract	 and	 on	 central	
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neurons	 of	 the	 lateral	 hypothalamus.	 Due	 to	 the	 short	 half-life	 of	 GLP-1,	 it	 is	 likely	 that	
signalling	 through	 local	 vagal	 afferents	 is	more	 physiologically	 relevant	 to	 gastrointestinal	
GLP-1	mediated	satiation	than	direct	action	on	the	central	nervous	system	[77,78].		
	
Regarding	 the	 other	 proglucagon-derived	 peptides	 that	 are	 secreted	 together	with	GLP-1	
from	 L-cells,	 whilst	 glicentin	 has	 no	 known	 receptor	 or	 physiological	 role,	 GLP-2	 has	 an	
intestinotrophic	effect	via	the	Gs-coupled	GLP-2	receptor.	This	effect	appears	 important	to	
the	 recovery	of	 intestinal	mucosa	 following	 injury	 [79,80].	Furthermore,	oxyntomodulin	 in	
both	rodent	models	and	human	volunteers,	mediates	loss	in	body	weight	(through	appetite	
suppression	 and	 increases	 in	 energy	 expenditure)	 and	 restoration	 of	 normoglycaemia.	
Oxyntomodulin	 treatment	 also	 appeared	 to	 have	 superior	 therapeutic	 effects	 to	 GLP1R-
selective	 incretin	 mimetics.	 These	 effects	 do	 not	 appear	 to	 be	 mediated	 by	 a	 specific	
oxyntomodulin	 receptor	 (which	 has	 not	 been	 identified	 to	 date),	 but	 by	 dual	 agonism	 of	
GLP1R	and	the	glucagon	receptor	(GCGR)	by	oxyntomodulin	[80,81].	Aiming	to	replicate	the	
weight	loss	and	improvements	in	glucose	tolerance	seen	with	oxyntomodulin	administration,	
synthetic	 GLP1R/GCGR	 dual	 agonists	 have	 recently	 been	 developed,	 an	 example	 being	
MEDI0382.	In	recent	clinical	trials,	MEDI0382	administration	induced	significant	weight	loss	




Figure	 3:	 Post-translational	 processing	 of	 the	 preproglucagon	 polypeptide	 in	 alpha	 cells,	
neurons	and	L-cells	of	the	gastrointestinal	tract.	Prohormone	convertase	2	(Psck2)	activity	in	
















co-secreted	 into	 the	 circulation	 with	 GLP-1	 by	 L-cells	 [67,68,70–72].	 Given	 that	 recent	
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with	 knockout	 of	 Rxfp4	 in	 mice	 abolishing	 INSL5-induced	 increases	 in	 food	 intake	 [88].	
Whether	INSL5	is	secreted	together	with	GLP-1	and	PYY	to	known	colonic	L-cell	stimulants	is	










contraction	of	 the	gallbladder)	 into	 the	duodenum	 [93].	 The	pancreatic	enzymes	 released	
catalyse	 the	 breakdown	of	macromolecules	 such	 as	 complex	 carbohydrates,	 proteins	 and	
lipids	 into,	 respectively,	 simple	 sugars,	 amino	 acids	 and	 free	 fatty	 acids	 (together	 with	
cholesterol	and	monoglycerides)	which	are	absorbed	across	the	small	intestinal	mucosa	[94].	
























gain,	 liver	 triglyceride/cholesterol	 accumulation	 and	 obesity-related	 insulin	 resistance	
compared	to	wild	type	mice	on	HFD.	In	part,	these	discrepancies	appear	to	result	from	the	
absence	of	neurotensin	facilitated	absorption	of	lipids	from	the	small	intestine.	Consistently,	







expected	 decrease	 in	 food	 intake	 associated	 with	 increased	 plasma	 levels	 of	 GLP-1	 and	
neurotensin.	Post-operative	pharmacological	antagonism	of	peripheral	neurotensin	signalling	




to	 patients	 with	 shorter	 biliopancreatic	 limbs	 [107].	 Combined,	 these	 findings	 imply	 that	






14)	 produced	 by	 truncation	 of	 SST-28	 [108,109].	 Cells	 which	 produce	 and	 secrete	
somatostatin	 are	 referred	 to	 henceforth	 as	 D-cells	 (historical	 term	 for	 somatostatin-
producing	 EECs).	 Radioimmunoassay	 analysis	 identified	 that	 gastrointestinal	 somatostatin	
equates	 to	 roughly	 65%	of	 the	 total	 somatostatin	 produced	 in	 the	 body	with	 the	 highest	
concentrations	found	in	the	gastric	antrum	and	distal	colon.	The	remaining	somatostatin	is	
partitioned	 between	 delta	 cells	 in	 pancreatic	 islets	 (5%)	 and	 neurons	 of	 central	 nervous	




global	 inhibitor	 of	 exocrine	 and	 endocrine	 secretions	 inhibiting	 the	 release	 of	 all	
enteroendocrine	 hormones,	 pancreatic	 glucagon	 and	 insulin	 secretion	 and	 gastric	 acid	




production	 such	 as	 hypoglycaemia	 resulting	 from	 insulinoma	 [112].	 In	 addition	 to	 dietary	
nutrients,	such	as	small	peptides,	many	endocrine	and	exocrine	hormones,	including	GLP-1	
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and	CCK,	stimulate	somatostatin	secretion	 forming	negative	 feedback	 loops	 [113–115].	As	




More	 than	 90%	 of	 the	 total	 serotonin	 (5-HT)	 in	 the	 body	 is	 produced	 by	 EECs	 of	 the	
gastrointestinal	epithelium	referred	to	in	this	thesis	as	enterochromaffin	cells	(EC	cells)	[116].	
These	 cells	 are	 found	 with	 highest	 incidence	 in	 the	 pylorus	 of	 the	 stomach	 and	 a	 fairly	























In	 order	 to	 examine	 the	 secretory	 mechanisms	 of	 human	 enterendocrine	 cells	 in	 vitro,	
immortalised	 cell	 line	 models,	 primary	 murine	 and	 human	 tissue	 samples	 and	 recently	









cells	 in	 which	 such	 mutations	 have	 already	 occurred.	 Additional	 experimental	 genetic	







cell	 lines	 produced	 pancreatic	 glucagon	which	 is	 absent	 in	 L-cells.	 This	 is	 consistent	 with	
GLUTag	and	STC-1	expression	of	proprotein	convertase	2	(PC2)	which	is	not	expressed	in	L-




Primary	 tissue	 based	 investigations	 of	 EEC	 secretory	 mechanisms	 have	 principally	 been	
conducted	through	generation	of	mixed	primary	cultures,	Ussing	chamber	experiments	and	
perfusion	 of	 isolated	 segments	 of	 gastrointestinal	 tissue.	 2D	 mixed	 primary	 cultures	 are	
generated	 from	 isolated	 gastrointestinal	 secretory	 glands	 and	 have	 been	 successfully	
generated	from	all	regions	of	the	murine	and	human	gastrointestinal	tracts	enabling	analysis	
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of	 stimuli/and	 or	 antagonists	 of	 specific	 transporters	 to	 either	 the	 apical	 or	 basolateral	
chambers	(which	is	not	possible	in	the	2D	primary	cultures)	[126].	The	epithelial	polarity	of	
EEC	responses	can	also	be	examined	using	buffer	perfused	isolated	sections	of	intestine	with	
the	 added	 advantage	 that	 the	 structural	 integrity	 of	 the	 intestine	 and	 the	 blood	 vessels	
supplying	it	are	largely	preserved	(for	Ussing	chamber	experiments	intestinal	tissue	must	be	
opened	up	and	flattened	and	usually	the	muscle	layers	and	vasculature	are	removed).	This	
allows	 stimuli	 to	 be	 directly	 administered	 either	 to	 the	 lumen	 or	 intravascularly	 [127].	 A	













Proliferation	 and	 differentiation	 of	 LGR5+	 cells	 is	 regulated	 by	 exposure	 to	 various	
modulators,	principally	by	the	signalling	peptides	Wnt,	bone	morphogenetic	protein	(BMP),	
epidermal	growth	factor	(EGF)	as	well	as	direct	cell-cell	Notch	signalling	(figure	4)	[131].	The	









small	 intestinal	 enteroendocrine	 cells	 according	 to	 placement	 along	 the	 crypt-villus	 axis	





LGR5+	 stem	 cells	 whilst	 increasing	 the	 numbers	 of	 enteroendocrine	 and	 goblet	 cells	
[135,136].	
	












Figure	 4:	 Schematic	 illustrating	 LGR5+	 cell	 differentiation	 into	 mature	 absorptive	 cells	
(enterocytes/colonocytes)	and	secretory	cells	(enteroendocrine	cells,	goblet	cells	and	Paneth	
cells).	 Wnt,	 epidermal	 growth	 factor	 (EGF)	 and	 Notch	 signalling	 promote	 LGR5+	 cell	
proliferation	whilst	bone	morphogenetic	protein	(BMP)	inhibits	proliferation.	Notch	signalling	
additionally	 promotes	 Hes1	 expression	 which	 represses	 expression	 of	 the	 secretory	 cell	
determinants	 Math1	 and	 Dil1.	 Secretory	 precursors	 can	 provide	 a	 reserve	 population	 of	
intestinal	stem	cells,	dedifferentiating	to	stem	cells	upon	tissue	injury.	Key	transcription	factors	







The	 investigations	 detailed	 in	 chapters	 3,	 4	 and	 5	 were	 designed	 to	 expand	 the	 current	



















































Spondin-1	 (Peprotech),	 1%	 penicillin/streptomycin	 (100	 units/ml;	 Invitrogen),	 2mM	 L-


















































in	 L-cells.	 GCaMPs	 (including	 GCaMP3)	 are	 chimeric	 proteins	 consisting	 of	 circularly	
permutated	GFP,	calmodulin	and	M13	(from	myosin	light	chain	kinase)	domains	[144–146].	
Under	 the	 condition	 of	 elevated	 intracellular	 calcium	 levels,	 calcium	 ions	 binding	 to	 the	
calmodulin	moiety	of	GCaMP	causes	a	conformational	change	in	GCaMP	that	reduces	solvent	
quenching	 of	 GFP	 fluorescence	 (when	 excited	 with	 488nm	 light)	 [147].	 Thus,	 when	
intracellular	 calcium	 levels	 increase	GCaMP	 fluorescence	 (when	excited	with	488nm	 light)	
also	 increases	 providing	 a	 proxy	 measure	 for	 intracellular	 calcium	 levels.	 Selective	 L-cell	
expression	 of	 GCaMP3	 was	 achieved	 by	 crossing	 Glu-Cre12	 mice	 with	 ROSA26-GCaMP3	












Insl5-rTA/TET-GCaMP6F∆CMV	mice	 (the	 CMV-Cre	 cross	 produced	 germ	 line	 deletion	 of	 a	
floxed	stop	codon	within	the	TET-GCaMP6F	cassette)	[151].	GCaMP6F	was	developed	from	
pre-existing	 GCaMP	 variants	 by	 mutagenesis	 and	 exhibits	 greater	 sensitivity	 and	 faster	
responses	 to	 intracellular	calcium	than	GCaMP3	[152].	 In	 the	 Insl5-rTA/TET-GFP	and	 Insl5-
rTA/TET-GCaMP6F∆CMV	mice	conditional	expression	of	GFP	and	GCaMP6F	is	limited	to	Insl5-
expressing	cells	upon	administration	of	tetracyclines	such	as	doxycycline	(figure	1B)	[153].	For	
FACS-isolation	 and	model	 verification	 by	 tissue	 section	 immunofluorescent	 labelling	mice	







































Single	 cell	 digests	 of	 murine	 colon	 were	 prepared	 for	 FACS	 purification	 by	 collagenase	
digestion.	 For	 purification	 of	 Insl5-expressing	 cells	 digests	 from	 mice	 orally	 dosed	 with	
doxycycline	prior	 to	 sacrifice	 (as	described	previously)	were	used.	 Single	 cell	 digests	were	
produced	by	serial	incubation	of	colonic	tissue	with	1mg/ml	collagenase	(dissolved	in	calcium-
free	HBSS)	at	37°C	and	 filtration	 through	50µm	 filters	 (to	 remove	 larger	debris).	 The	 final	
digest	was	spun	at	300g	for	10	minutes,	resuspended	in	HBSS	(calcium-free)	with	10%	FBS	(to	
reduce	cell	clumping	and	adhesion	to	plasticware)	and	10µM	Y-27632	(to	prevent	anoikis)	





Single	 cell	 suspensions	 were	 sorted	 using	 an	 Influx	 Cell	 Sorter	 (BD	 Biosciences)	 at	 the	
Cambridge	Institute	of	Medical	Research	(CIMR)	Flow	Cytometry	Core	Facility.	DAPI-staining,	
DRAQ5-staining	 (only	 for	 the	NeuroD1-EYFP	 sort),	 side	 scatter,	 forward	 scatter	 and	 pulse	
width	gates	were	applied	 to	 remove	clustered	cells	 and	any	 cellular	debris	present.	 Insl5-
expressing	 cells	 (from	 Insl5-rTA/TET-GFP	 and	 Insl5-rTA/TET-GCaMP6F∆CMV	 mice)	 were	
isolated	 by	 GFP	 fluorescence	 into	 RLT	 plus	 lysis	 buffer	 (Qiagen)	 enriched	 with	 1%	 β-
mercaptoethanol.	 GFP-ve	 cells	 were	 also	 isolated	 as	 a	 control	 population	 for	 the	
transcriptomic	analysis	of	INSL5-producing	cells.	Neurod1-expressing	cells	(from	a	NeuroD1-











































were	moved	 to	 fresh	PBS	 in	50ml	 falcon	 tubes	and	shaken	 for	~12	seconds.	The	 resulting	







48-well	 plates	were	 incubated	 at	 37˚C	 for	 30	minutes	 to	 enable	matrigel	 polymerisation.	








3	 minutes.	 Subsequently	 the	 TrypLE	 express	 enzyme	 was	 neutralised	 by	 addition	 of	
neutralisation	media	and	titriated	with	P1000	tips.	The	digest	was	then	centrifuged	at	200g	








ADF	 to	 dissolve	 the	matrigel	 matrix.	 Following	 centrifugation	 at	 200g	 for	 5	 minutes,	 the	



























































































incubated	 at	 37°C	 for	 1	 hour.	 The	 plate	 was	 then	 placed	 on	 ice	 and	 treatments	 were	
transferred	to	LoBind	1.5ml	tubes	(Eppendorf;	reduced	peptide	loss)	and	centrifuged	at	2000g	
for	5	minutes	at	4°C	to	remove	cellular	debris.	500µl	of	each	supernatant	were	collected	into	
fresh	1.5ml	LoBind	 tubes.	Meanwhile,	200µl	 lysis	buffer	was	added	 to	each	well.	After	30	






µElution	 SPE	 plates	 (Waters)	 according	 to	 the	 manufacturer’s	 instructions.	 Elution	 was	



















the	A-chain	of	 INSL5	was	quantified	 (fragment	most	 consistently	detected)	 and	NTS	 (with	
terminal	glutamine	transformed	into	pyroglutamate)	was	additionally	quantified.	All	readings	
were	 normalised	 by	 the	 internal	 standard	 measurements.	 Total	 protein	 content	 was	
calculated	 from	 lysate	 supernatants	 using	 a	 BCA	 protein	 assay	 (Thermo	 Fisher	 Scientific)	
which	 was	 used	 to	 normalise	 secretory	 responses	 between	 different	 wells	 (account	 for	
differences	in	cellular	content).		
	









significant	 INSL5,	 PYY	 and	 NTS	 secretory	 responses	 (compared	 to	 basal	 secretion)	 were	




































Insl5-rtTA/TET-GCaMP6F∆CMV	mice	were	 orally	 treated	with	 3mg/ml	 doxycycline	 for	 5-7	
days	 prior	 to	 sacrifice	 and	whole	 colon	 excision.	 Following	 removal	 of	 adipose	 tissue	 and	
muscle	 layers	 colons	 were	 fixed	 in	 4%	 PFA	 (Alfa	 Aesar)	 overnight	 at	 4°C.	 The	 tissue	 was	
subsequently	 dehydrated	 using	 a	 sucrose	 gradient	 firstly	 by	 placement	 in	 15%	 sucrose	
(dissolved	in	PBS)	for	5-6	hours	at	4°C,	followed	by	incubation	in	30%	sucrose	(dissolved	in	
PBS)	overnight	at	4°C.	Following	dehydration,	the	tissue	was	embedded	in	OCT	creating	blocks	




Immunofluorescent	 labelling	 of	 tissue	 sections	 was	 achieved	 in	 a	 similar	 manner	 as	 for	
primary	cultures	except:	1	hour	block	steps,	overnight	 incubation	with	primary	antibodies	































Table	1:	 Primary	antisera	used	 for	 immunofluorescent	 labelling.	Note	1:1000	of	 the	 INSL5	
primary	antibody	was	used	for	the	3D-SIM	and	wholemount	samples	whilst	1:2000	was	used	










Antigen Raised	in Concentration Source
Proglucagon Rabbit 1:200 Santa	Cruz	sc13091
GFP Goat 1:1000 AbCam	Ab5450
INSL5 Rat 1:1000/1:2000 Takeda
PYY Guinea	Pig 1:500 Progen	16066
NTS Rabbit 1:100 Merck	AB4596













Prior	 to	 analysis,	 primary	 and	 2D	 organoid	 cultures	 were	 equilibrated	 with	 saline	 buffer	
containing	 1mM	 glucose	 for	 30	 minutes.	 Following	 this,	 treatments	 were	 applied	 at	 a	
perfusion	 rate	 of	 1ml/minute.	 All	 treatments	 were	 made	 up	 in	 saline	 with	 added	 1mM	
glucose.	 Changes	 in	 GCaMP3/GCaMP6F	 fluorescence	 (proxy	 to	 intracellular	 Ca2+	 levels)	





(with	 10µM	 Y-27632)	 for	 the	 primary	 and	 2D	 organoid	 cultures	 respectively.	 Intracellular	




To	 examine	 the	 effect	 of	 concomitant	 activation	 of	 GPBAR-1	 on	 intracellular	 calcium	
responses	to	10µM	TAK-875	and	30mM	KCl	cells	were	first	stimulated	with	either	10µM	TAK-
875	or	30mM	KCl	alone.	Following	saline	buffer	washout,	cells	were	pre-treated	with	3µM	

























Black	 (Zeiss).	 For	 the	 surfaces	 analysis,	 chromatic	 abberations	 were	 adjusted	 for	 by	



















mean	3D	positions	of	all	 the	vesicles	 in	each	of	the	channels	for	every	 image	analysed.	To	
remove	erroneously	localised	vesicles,	if	the	positions	of	the	channel	signals	for	a	particular	
identified	 vesicle	 were	 >200nm	 apart	 they	 were	 considered	 to	 originate	 from	 different	
vesicles	and	therefore	discarded.	The	channel	intensities	of	each	image	were	normalised	to	a	
0-1	 scale	by	 reference	 to	 the	 image’s	maximum	 intensity	pixel.	 Subsequently	 the	 channel	
intensities	were	determined	for	each	vesicle	by	calculating	the	mean	pixel	intensity	within	a	
150	nm	radius	sphere	centred	at	the	identified	vesicle	centre	point,	followed	by	background	



















focus	 (EDF)	 images	 were	 taken	 for	 each	 of	 the	 three	 labelled	 channels	 using	 a	 Plan-
ApoChromat	 20x/0.8	 M27	 objective,	 a	 Hamamatsu	 Orca	 Flash	 camera	 and	 an	 inbuilt	








spatial	analysis	was	used	to	 identify	cells	 labelled	 in	each	of	the	three	channels	(reflecting	
staining	 for	NTS,	PYY	and	 INSL5).	Afterwards,	using	 INSL5	and	NTS	staining	as	 the	primary	
labels,	dual	 labelled	cells	were	 identified.	Following	on	from	this,	 triple	 labelled	cells	were	

























for	 samples	 from	 FACS-purified	 cells	 using	 a	 Peltier	 Thermal	 Cycler-225	 (MJ	 Research)	
according	 to	 standard	 protocols.	 All	 RNA	 samples	 from	 FACS-purified	 cells	 were	 quality	
checked	by	using	a	Bioanalyser	RNA	Pico	Kit	(Agilent)	with	all	RIN	values	above	7.3.	RT-qPCR	
was	undertaken	using	the	QuantStudio	7	flex	RT-qPCR	system	(Applied	Biosystems).	The	RT-
qPCR	 reaction	 mix	 consisted	 of	 template	 cDNA,	 TaqMan	 Universal	 Master	 Mix	 (Applied	
Biosystems)	and	specific	primers	(Applied	Biosystems)	which	are	detailed	in	table	2.		
	




gene	 expression	 along	 the	 colonic	 proximal-distal	 axis	 (P1-P7	 segments),	 statistically	
significant	(p<0.05)	differences	in	regional	∆CT	values,	with	reference	to	the	most	proximal	










































Figure	 3:	 Schematic	 illustrating	 how	 the	 10x	 Chromium	 system	 generated	 single	 cell	









the	 Chromium	 system	 (10x	 Genomics)	 producing	 cDNA	 libraries	 which	 were	 paired-end	
sequenced	by	a	HiSeq	4000	(Illumina)	at	the	Cancer	Research	UK	Cambridge	Institute	(CRUK	
CI).	Quality	control,	 read	alignment	 (with	 reference	 to	 the	mm10	genome)	and	raw	count	




likely	 within	 the	 microfluidics	 chip.	 A	 mean	 of	 190279	 reads	 was	 achieved	 for	 the	 cells	














package	 [159].	 Raw	 counts	 were	 firstly	 normalised	 using	 the	 trimmed	mean	 of	M-values	
normalisation	method	(TMM)	and	then	fitted	to	a	negative	binomial	generalised	log-linear	
model	 (using	 the	 glmFit	 function).	 Following	 this,	 gene-wise	 likelihood	 ratio	 tests	 were	
performed	(using	the	glmLRT	function)	to	examine	statistical	differences	in	gene	expression	
between	one	reference	group	and	all	the	other	groups.	These	tests	were	repeated	so	that	
gene	 expression	 was	 compared	 between	 all	 groups.	 Subsequently,	 genes	 with	 a	 false	
discovery	rate	(FDR)	above	0.01	were	excluded	and	the	top	10	most	differentially	expressed	
genes	 were	 identified	 for	 each	 group.	 Additionally,	 by	 subsetting	 genes	 encoding	 GPCRs	
(appendix	 3)	 and	 transporters,	 the	 top	 10	 most	 differentially	 expressed	 GPCRs	 and	
transporters	were	identified	for	each	group.	Visual	representation	of	differentially	expressed	













As	 previously	 discussed,	 luminal	 contents	 of	 the	 intestine	 and	 circulating	 factors	 can	 be	
sensed	by	 L-cells	 through	 activation	of	 both	Gq	 and	Gs	 coupled	GPCRs	 [55].	 Simultaneous	
activation	of	the	Gq	and	Gs	signalling	pathways	by	dietary	stimuli	raises	the	possibility	of	cross-





875	(AKA	fasiglifam)	and	AR231453	respectively	 [160].	 In	this	chapter,	 the	hypothesis	that	
synergy	 exists	 between	 the	 signalling	 pathways	 of	 FFAR1	 and	 the	 Gs-coupled	 bile	 acid	
receptor	 GPBAR-1	 is	 examined	 through	 intracellular	 calcium	 imaging	 and	GLP-1	 secretion	
assays.	Clinically,	combination	therapy	might	enable	exploitation	of	such	synergy	for	type	2	
diabetes	treatment.	This	approach	could	potentially	reduce	adverse	effects	associated	with	













as	 esters	 such	 as	 triglycerides,	 phospholipids	 and	 cholesterol.	 Ingested	 triglycerides	 are	
digested	to	2-monoacylglycerol	(2-MAG)	and	free	fatty	acids	(FFAs).	Free	fatty	acids	(FFAs)	
compose	a	group	of	hydrocarbons	divided	by	the	number	of	constituent	carbon	atoms	into	
small	 (<8	 carbons;	 SCFAs),	medium	 (8-12	 carbons;	MCFAs)	 and	 long	 (>12	 carbons;	 LCFAs)	
chain	 fatty	 acids	 [161].	 Unlike	MCFAs	 and	 LCFAs,	 volatile	 SCFAs	 are	 products	 of	 bacterial	
fermentation	in	the	large	intestine	and	contribute	~10%	total	daily	calorie	intake	in	humans	






action	 is	 facilitated	 through	 lipid	 emulsification	 by	 bile	 acids	 produced	 by	 the	 liver	 from	
cholesterol.	Produced	bile	acids	are	stored	in	the	gallbladder	between	meals	and	enter	the	
duodenum	 via	 the	 common	 bile	 duct.	 CCK,	 released	 postprandially	 in	 the	 proximal	 small	
intestine,	 stimulates	 gallbladder	 contraction	 and	 subsequent	 bile	 secretion	 into	 the	
duodenum	[164].	These	amphipathic	molecules	act	as	surfactants	forming	small	micelles	thus	




binding	 proteins	 (FABPs)	 in	 the	 cytosol	 which	 act	 as	 chaperones	 [168].	 Directed	 to	 the	
endoplasmic	 reticulum	 (ER),	 triglycerides	 are	 synthesised	 from	 the	 FFAs	 and	 2-MAG	 and	











conditions	 such	 as	 functional	 constipation	 since	 ASBT	 inhibition	 attenuates	 bile	 acid	
reabsorption	 resulting	 in	 accelerated	 colonic	 transport	 [170].	 Alternatively,	 bile	 acids	
conjugated	to	taurine	or	glycine	can	be	passively	absorbed	across	the	apical	brush	border	via	
diffusion	[171].	As	with	FFAs,	bile	acids	are	sequestered	within	the	cytosol	by	ileal	bile	acid	








Figure	1:	 Schematic	 illustrating	 the	mechanisms	 involved	 in	 lipid	digestion	and	absorption	
within	the	small	intestine	and	receptors	involved	in	L-cell	chemosensation	of	free	fatty	acids	




synthesised	 from	 absorbed	 FFAs	 and	 2-MAG	 and	 packaged	 into	 prechylomicrons	 in	 the	
endoplasmic	 reticulum.	 These	 prechylomicrons	 are	 subsequently	 processed	 by	 the	 Golgi	
complex	 into	 chylomicrons	 which	 are	 exocytosed	 from	 the	 basolateral	 membrane	 into	





















plasma	GIP/GLP-1	responses	 to	high	 fat	diet	 (administered	via	gavage)	 [175].	Additionally,	
application	of	FFAR1/FFAR4	dual	agonists	 to	human	colonic	crypt	cultures	 triggered	GLP-1	
secretion	 [70].	 FFAR4	 appears	 to	 be	 play	 a	 less	 significant	 role	 in	 FFA-mediated	 GLP-1	







FFAR1	 agonists,	 including	 TAK-875	 and	 linoleic	 acid,	 were	 applied	 to	 perfused	 rat	 small	
intestine,	 GLP-1	 secretion	 was	 only	 triggered	 by	 vascular	 administration	 and	 not	 luminal	
administration	 [127].	 Such	 results	 imply	 that	 FFAs	 are	 not	 sensed	 by	 L-cells	 luminally	 but	
basolaterally	following	absorption.	In	support	of	this	Psichas	et	al.	suggest	that	FFA	liberation	
from	 chylomicrons	 at	 the	basolateral	membrane	by	 local	 lipoprotein	 lipase	 facilitates	 FFA	
sensing	 through	 FFAR1	 [177].	 However,	 support	 for	 this	 mechanism	 is	 compounded	 by	
evidence	 that	 orlistat	 (lipase	 inhibitor)	 does	 not	 attenuate	 GLP-1	 secretion	 from	 murine	
intestinal	 cultures	 [177].	 Furthermore,	 given	 the	 low	 bioavailability	 of	 orlistat,	 a	 study	 by	
Ellrichmann	et	al.	(2008)	on	healthy	humans	suggests	that	pancreatic	lipases	might	be	more	
significant	 to	 FFA-mediated	 GLP-1	 release	 as	 oral	 orlistat	 administration	 attenuated	
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postprandial	increases	in	plasma	GLP-1	[178].	Contrastingly,	Damci	et	al.	(2004)	found	that	
oral	 orlistat	 administration	 increased	 postprandial	 plasma	 GLP-1	 levels	 in	 type	 2	 diabetic	
patients	[179].	This	increase	in	GLP-1	release	could	derive	from	increased	delivery	of	lipids	to	
the	 L-cell	 rich	 distal	 gastrointestinal	 tract.	 It	 is	 possible	 that	 the	 discrepancies	 in	 findings	
between	 the	 Damci	 et	 al.	 (2004)	 and	 Ellrichmann	 et	 al.	 (2008)	 studies	 reflect	 nutritional	
differences	in	the	diets	employed.	The	diet	in	the	Damci	et	al.	study,	for	example,	contained	
higher	 levels	of	 fat	 than	 in	the	Ellrichmann	et	al.	study.	 In	 light	of	 the	contrasting	findings	




islets	 whereby	 stimulation	 of	 FFAR1	 with	 the	 FFAR1	 specific	 agonist	 TAK-875	 enhanced	
glucose-induced	 insulin	 stimulation	 from	 isolated	 islets	 [180,181].	 Under	 physiological	








with	 type	 2	 diabetes	 [182].	 Together	 these	 results	 further	 highlight	 the	 physiological	 and	
clinical	relevance	of	FFAR1.	
	
With	 regards	 to	 the	 effects	 of	 bile	 acids	 on	 intestinal	 L-cells,	 treatment	 of	 primary	 small	
intestinal	crypt	cultures	with	bile	acids	such	as	taurodeoxycholic	acid	(TDCA)	stimulates	GLP-
1	secretion.	This	stimulation	appears	GPBAR-1	dependent	as	GPBAR-A	(a	specific	agonist	of	
GPBAR-1)	 triggers	GLP-1	 secretion	and	primary	 cultures	 generated	 from	Gpbar1	 knockout	
mouse	 did	 not	 display	 GLP-1	 responses	 to	 TDCA	 (or	 GPBAR-A).	 Acute	 L-cell	 secretory	
responses	to	bile	acids	appear	not	to	be	mediated	by	the	nuclear	receptor	for	bile	acids,	FXR	
[126].	Ussing	chamber	experiments	whereby	a	piece	of	suspended	small	intestine	epithelium	
separates	 two	 chambers	 of	 buffer,	 one	 apically	 facing	 and	 the	 other	 basolaterally	 facing,	
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enabled	the	polarity	of	the	small	intestinal	bile	acid	responses	to	be	examined.	GPBAR-A	only	








FFAs	 and	 bile	 acids	 reach	 the	 small	 intestinal	 mucosa	 in	 parallel	 raising	 the	 prospect	 of	
concomitant	activation	of	the	Gs	and	Gq	signalling	pathways	under	physiological	conditons.	
Synthetic	 full	 agonists	 of	 FFAR1	 such	 as	 AM-1638,	which	 can	 employ	 both	 the	Gq	 and	Gs	
signalling	pathways	trigger	significantly	greater	GLP-1	secretion,	from	colonic	crypt	cultures	
and	 in	 vivo	 following	 oral	 gavage,	 than	 partial	 agonists	 like	 TAK-875	 which	 activate	 Gq-
signalling	 alone	 [173,185].	 It	 should	 be	 noted	 that	 in	 experiments	 where	 AM-1638	 was	
applied	 to	 L-cells	 in	 primary	 culture	 increases	 in	 intracellular	 cAMP	 were	 not	 observed	
contrasting	 with	 previous	 studies	 (unpublished	 data	 by	 Gwen	 Tolhurst).	 This	 discrepancy	








intestinal	 apical	 brush	 border	 simultaneously	 with	 FFAs	 meaning	 GPR119-mediated	
potentiation	 of	 FFAR1-mediated	 GLP-1	 release	 has	 physiological	 relevance.	 TAK-875	 was	
withdrawn	from	phase	III	clinical	investigations	because	of	issues	with	liver	toxicity	and	such	
synergy	 suggests	 that	 a	 lower,	 possibly	 non-toxic,	 therapeutic	 dose	 of	 TAK-875	 could	 be	




recently	 been	 developed	 for	 the	 treatment	 of	 obese	 type	 2	 diabetes	 and	 appear	 more	













signalling,	 DAG,	 activates	 protein	 kinase	 C	 and	 can	 directly	 activate	 certain	 TRP	 cation	
channels	which	depolarise	the	plasma	membrane	[191].	This	could	explain	how	inhibition	of	
the	protein	kinase	C	variant	PKCzeta,	significantly	attenuated	oleic	acid	(a	LCFA)	induced	GLP-
1	 secretion	 from	GLUTag	cells	 [192].	 Synergistic	 interactions	between	Gq	and	Gs	 signalling	
likely	arise	 from	 integration	of	 the	actions	of	 their	effector	proteins	 resulting	 in	 increased	
exocytotic	 activity.	 Such	 cross-talk	 has	 been	 observed	 before	 for	 example	 in	 cardiac	
fibroblasts	and	mast	cells	[193,194].	Potential	synergistic	effects	of	FFAR1	and	GPBAR-1	co-












Goldspink.	 Responses	 are	 quoted	 as	mean	 fold	 changes	 (from	 basal)	 ±	 SEM.	 All	 the	 fold	
changes	 in	 fluorescence	 quoted	 in	 the	 following	 sections	 reflect	median	 values	with	 95%	
confidence	interval	(CI)	in	parentheses.		
	
 Bile	 acids	 and	 FFAR1	 agonists	 elicit	 intracellular	 calcium	 responses	 in	
organoid-derived	L-cells	
Immunofluorescent	 labelling	of	proglucagon	and	GCaMP3	revealed	selective	expression	of	
GCaMP3	 in	 organoid	 cultured	 ileal	 L-cells	 (figure	 2A).	 Organoid-derived	 L-cells	 exhibited	
significant	calcium	responses	(figure	2B&C)	to	application	of	10µM	of	the	bile	acid	TDCA	which	
triggered	a	median	 fold	 increase	of	1.63	 (CI=1.07-2.04)	 in	GCaMP3	fluorescence.	Similarly,	
application	 of	 3µM	 AM-1638	 drove	 a	 1.45	 (CI=1.16-3.01)	 fold	 increase	 in	 GCaMP3	
fluorescence.	All	cells	included	in	the	analysis	responded	to	one	of	the	positive	controls	which	
were	100nM	bombesin	and	30mM	KCl.	100nM	bombesin	and	30mM	KCl	application	triggered	
1.51	 (CI=1.32-1.65)	 and	 1.35	 (CI=1.22-1.55)	 fold	 increases	 in	 GCaMP3	 fluorescence	
respectively.	 The	 0.1%	 DMSO	 vehicle	 control	 triggered	 significant	 changes	 in	 intracellular	









hour	 at	 room	 temperature	 with	 1:300	 of	 goat-raised	 secondary	 antibodies	 conjugated	 to	
AlexaFluor	488	and	555	respectively.	Nuclear	staining	was	achieved	by	a	further	10	minute	
incubation	 with	 1:1300	 Hoescht	 nuclear	 stain.	 (B)	 Representative	 trace	 from	 a	 calcium	
imaging	experiment	on	2D	monolayer	cultured	ileal	organoids	derived	from	Glu-Cre	x	Rosa26-































































































































30mM	 potassium	 chloride	 (KCl).	 FI/FI0	 plotted	 on	 y-axis	 reflects	 the	 maximum	 measured	
GCaMP3	fluorescence	during	drug	application	divided	by	the	maximum	measured	during	a	30	
second	 period	 prior	 to	 drug	 application	 i.e.	 fold	 change	 in	 fluorescence.	Median	 and	 IQR	
reflected	 by	 central	 line	 and	 whiskers.	 Red	 dotted	 line	 marks	 FI/FI0=1	 i.e.	 no	 change	 in	
fluorescence	from	baseline.	n	=	number	of	cells.	Statistical	significance	assessed	using	Kruskal-





1.12	 (CI=1.03-1.32)	 and	 1.07	 (CI=1.02-1.42)	 fold	 increases	 in	 GCaMP3	 fluorescence	
respectively	(figure	3B).	Following	pre-incubation	with	3µM	GPBAR-A,	co-application	of	10µM	
TAK-875	 with	 3µM	 GPBAR-A	 elicited	 1.33	 (CI=1.26-1.98)	 fold	 increases	 in	 GCaMP3	
fluorescence	(figure	3B).	On	average	these	responses	were	4.91	(CI=1.28-11.81)	fold	higher	
than	the	anticipated	response	in	488	fluorescence	(sum	of	the	steady	state	GPBAR-A	and	1st	
TAK-875	 responses)	 indicating	 that	 GPBAR-A	 potentiated	 L-cell	 intracellular	 calcium	
responses	to	TAK-875	(figure	3C).	Comparison	of	responses	to	the	1st	TAK-875	(before	GPBAR-
A	addition)	and	3rd	TAK-875	(after	GPBAR-A	washout)	applications	did	not	identify	a	significant	














GPBAR-A	 steady	 state	 and	 other	 groups	 assessed	 using	 Kruskal-Wallis	 test.	 #	 indicates	
significant	(p<0.05)	individual	responses	for	each	group	assessed	via	Wilcoxon	test	examining	











(CI=1.02-1.25)	 fold	 increases	 in	GCaMP3	fluorescence	 (figure	4B).	Responses	 to	30mM	KCl	













to	 the	 maximum	 fold	 change	 in	 fluorescence	 of	 GPBAR-A	 measured	 in	 the	 30	 seconds	




fluorescence	 from	 baseline.	 n	 =	 number	 of	 cells.	 Statistical	 significance	 assessed	 between	
GPBAR-A	 steady	 state	 and	 other	 groups	 assessed	 using	 Kruskal-Wallis	 test.	 #	 indicates	
significant	(p<0.05)	individual	responses	for	each	group	assessed	via	Wilcoxon	test	examining	
deviation	of	median	values	 from	1	 (i.e.	no	change	 in	GCaMP3	 fluorescence).	 (C)	Degree	of	
potentiation	 of	 responses	 to	 KCl	 by	 co-application	with	 GPBAR-A.	 y-axis	 reflects	 the	 ratio	
between	 the	maximum	 fold	 change	 in	 GCaMP3	 fluorescence	 during	 KCl	 and	GPBAR-A	 co-
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application	and	the	anticipated	fold	change	in	fluorescence,	calculated	from	the	sum	of	the	










10µM	 TAK-875	 application	 elicited	 1.49	 ±	 0.08	 fold	 increases	 in	 GLP-1	 secretion.	 Co-
application	of	3µM	GPBAR-A	with	10	µM	TAK-875	yielded	a	6.41	±	0.78	fold	increase	in	GLP-







secretion	 responses	 to	 10µM	 TAK-875	 and	 3µM	 GPBAR-A	 applied	 with	 10µM	 TAK-875.	
Statistical	significance	assessed	on	log	transformed	values.	Two-tailed	t-test	used	to	assess	
deviations	in	individual	group	means	from	1	(no	change	in	secretion).	Intergroup	comparisons	
made	 using	 a	 one-way	 ANOVA	 test	 with	 Dunnett’s	 correction.	 10µM	 forskolin	 (fsk)/IBMX	
acted	as	a	positive	 control	 for	GLP-1	 secretion.	 (C)	Potentiation	of	 TAK-875	 induced	GLP-1	
secretion	by	GPBAR-A.	Values	plotted	derive	from	percentage	of	GLP-1	secretion	measured	
from	 the	 combined	 TAK-875/GPBAR-A	 condition	 divided	 by	 that	 anticipated	 from	 the	
individual	GLP-1	secretory	responses	to	TAK-875	and	GPBAR-A.	A	two-tailed	t-test	was	used	
to	assess	deviation	from	1	(no	potentiation).	**p<0.01,	***p<0.001,	#p<0.05.	n=number	of	
wells.	 Bars	 represent	 mean	 ±	 SEM.	 Red	 dotted	 line	 marks	 y=1.	 Secretions	 performed	 in	
conjunction	with	Deborah	Goldspink.	









(2015)	 used	 small	 intestinal	 organoids	 to	 examine	 GLP-1	 secretory	 responses	 to	 applied	
glucose	and	the	dipeptide	gly-sar.	Small	intestinal	organoids	developed	from	Sglt1	and	Pept1	
knockout	 mice	 exhibited	 impaired	 GLP-1	 secretory	 responses	 to	 glucose	 and	 gly-sar	
respectively.	The	Sglt1	and	Pept1	knockout	organoids	also	demonstrated	impaired	epithelial	











paracrine	 signals	 that	 trigger	 elevate	 intracellular	 calcium	 levels	 in	 neighbouring	 L-cells.	
Alternatively,	the	GPBAR-A	induced	intracellular	calcium	transients	observed	here	(figure	4B)	






This	 raises	 the	possibility	 that	 a	 component	of	bile	 acid	 stimulated	GLP-1	 secretion	might	
	 66	
occur	independently	of	GPBAR-1	signalling.	However,	Brighton	et	al.	(2015)	found	that	bile	
acid	 triggered	GLP-1	 secretion	was	 abolished	 in	Gpbar1	knockout	mice	 implying	GPBAR-1	
signalling	as	essential	to	GLP-1	responses	to	bile	acids.	Thus,	it	is	unlikely	that	any	potential	
GPBAR-1	 independent	 bile	 sensing	mechanism	 triggers	GLP-1	 secretion	 in	 the	 absence	 of	
functional	GPBAR-1.	Alternatively,	the	larger	intracellular	calcium	transients	elicited	by	TDCA	
compared	to	GPBAR-A	application	may	reflect	modulation	of	GPBAR-1	signalling	by	GPBAR-1	
independent	 bile	 sensing	 mechanisms.	 Brighton	 et	 al.	 have	 ruled	 out,	 through	
pharmacological	manipulation,	 contribution	of	 farnesoid	X	 receptor	 (the	other	known	bile	








responses	 in	 1mM	 glucose	 but	 strong	 responses	 in	 the	 presence	 of	 3mM	 glucose	 [197].	
Sakuma	et	al.	attribute	the	basis	of	this	dependency	on	glucose-dependent	closure	of	KATP	
channels	 studding	 the	 plasma	membrane.	 This	 has	 the	 effect	 of	 depolarising	 the	 plasma	







Co-application	of	GPBAR-A	 (activating	GPBAR-1)	 and	 TAK-875	 (activating	 FFAR1)	 triggered	





potentiation	 of	 GLP-1	 secretion	 from	 small	 intestinal	 cultures	 and	 extended	 our	 findings	





(2018)	 further	 highlights	 the	 clinical	 potential	 of	 combination	 therapy.	 In	 this	 study,	 co-
administration	of	a	SSTR5	antagonist	(inhibiting	SSTR5	mediated	Gi	signalling)	together	with	
GPBAR-1	and	FFAR1	agonists	(stimulating	Gs	and	Gq	signalling)	and	a	DPP-4	inhibitor	enhanced	
GLP-1	 release.	 These	 findings	 suggest	 that	 the	 synergy	 between	 GPBAR-1	 and	 FFAR1	





Curiously,	 L-cells	 from	 Gpbar1	 knockout	 mice	 exhibit	 attenuated	 intracellular	 calcium	
responses	 to	KCl	application	 raising	 the	possibility	 that	GPBAR-1	can	enhance	 intracellular	
calcium	 responses	 by	 raising	 intracellular	 cAMP	 levels	 in	 the	 absence	 of	 bile	 acids	









examination	 of	 ileal	 L-cells	 (in	 organoid	 culture)	 suggests	 that	 the	 non-selective	 cation	
channel	TRPC3	and	voltage	gated	calcium	channels	are	 involved	[201].	Transcripts	 for	P/Q	
calcium	channel	subunit	such	as	Cacna1a	predominate	the	calcium	channel	profiles	in	both	




measured	Ca2+	 currents	whereas	 the	L-type	calcium	channel	blocker	 isradipine	had	only	a	
marginal	effect.	However,	GPBAR-A	induced	inward	calcium	currents	(~20%	increase)	which	
were	 blocked	 by	 the	 L-type	 calcium	 channel	 blocker	 nifedipine	 implying	 L-type	 calcium	
channel	 modulation	 by	 GPBAR-A.	 This	 likely	 reflects	 downstream	 PKA	 activity	 as	
phosphorylation	by	PKA	is	known	to	increase	the	activity	of	L-type	calcium	channels	[202].		
Supporting	 this	 hypothesis,	 application	 of	 H-89	 (a	 PKA	 inhibitor)	 to	 ileal	 crypt	 cultures	
significantly	attenuated	GPBAR-A	dependent	GLP-1	secretion.	Concerning	FFAR1	signalling,	
pharmacological	 blockade	 of	 TRPC3	 using	 pyr3	 significantly	 attenuated	 TAK-875	 induced	
inward	 currents	 and	 GLP-1	 secretion	 from	 primary	 ileal	 crypt	 cultures	 [201].	 Further	
experiments	examining	the	effects	of	the	membrane	permeable	TRPC3	activator	1-oleoyl-2-








potentiation	of	 the	 intracellular	 calcium	 responses	 to	30mM	KCl	 application	may	 similarly	
reflect	 GPBAR-A	 mediated	 modulation	 of	 L-type	 calcium	 channel	 kinetics.	 However,	 the	
proposed	mechanism	(figure	6)	is	questioned	by	evidence	that	co-application	of	the	L-type	
calcium	channel	activator	Bayk8644	with	TAK-875	did	not	trigger	synergy	in	GLP-1	secretion	
[201].	 Whilst	 Bayk8644	 is	 known	 to	 have	 off-target	 effects	 on	 voltage-gated	 potassium	
channels,	 these	 results	 could	 reflect	 alternative	 cross-talk	 mechanisms	 downstream	 of	
GPBAR-1	and	FFAR1	activation	[203].		
	
Alternative	 cAMP-dependent	 signalling	 mechanisms	 potentially	 involved	 include	 PKA	
modulation	 of	 the	 activities	 of	 SNARE	 proteins	 involved	 in	 vesicle	 docking,	 priming	 and	
exocytosis.	Such	mechanisms	are	known	to	promote	neurotransmission	and	possibly	renin	
secretion	from	juxtaglomerular	cells	[204,205].	PKA-independent	mechanisms	are	also	likely	
involved	 since	H-89	application	does	not	 completely	 abolish	GLP-1	 responses	 to	GPBAR-A	
	 69	
[201].	cAMP	is	also	known	to	directly	modulate	the	activities	of	hyperpolarisation-activated	
cyclic	 nucleotide-gated	 (HCN)	 channels.	 However,	 whilst	 cAMP	 appeared	 to	 activate	




Another	 possibility	 is	 that	 the	 PKA-independent	 effects	 of	 GPBAR-1	 activation	 observed	
involve	 the	 cAMP	effector	 EPAC2.	 EPAC2	 function	has	 been	 examined	 in	 pancreatic	 islets	
through	 knockdown	 of	 Rapgef4	 (the	 gene	 encoding	 EPAC2).	 Interestingly,	 these	 studies	
indicate	 that	a	significant	component	of	GLP-1	 induced	potentiation	of	glucose-stimulated	
insulin	 secretion	 depends	 on	 EPAC2	 activity	 (PKA	 involvement	 was	 also	 identified).	




These	 results	 suggest	 that	 EPAC2	 (together	 with	 PKA)	 is	 involved	 in	 mediating	 synergy	
between	Gq	and	Gs	signalling	pathways	in	pancreatic	beta-cells.	One	can	therefore	postulate	
that	EPAC2	may	perform	an	analogous	role	in	L-cells,	mediating	synergy	between	GPBAR-1	

































Small	 intestinal	 organoids	 provide	 a	 physiologically	 relevant	 platform	 to	 investigate	 L-cell	
physiology	 as	 evidenced	 here	 by	 observed	 intracellular	 calcium	 and	 GLP-1	 responses	 to	
known	GLP-1	secretagogues.	Using	this	platform,	synergistic	effects	of	GPBAR-1	and	FFAR1	
co-activation	 on	 both	 intracellular	 calcium	 responses	 and	GLP-1	 secretion	were	 identified	
confirming	the	primary	hypothesis	of	this	chapter.	Such	synergy	likely	occurs	physiologically	
as	 bile	 acids	 and	 FFAs	 arrive	 in	 the	 small	 intestinal	 lumen	 concomitantly.	 Further	




























INSL5-producing	 cells	 comprise	 roughly	 half	 of	 the	 colonic	 L-cell	 population.	 It	 has	 not	
previously	been	established	whether	these	cells	express	a	similar	or	different	repertoire	of	
GPCRs	 to	 non-INSL5	 producing	 colonic	 L-cells.	 Attempts	 to	 measure	 INSL5	 secretory	
responses	have	previously	been	hampered	by	a	 lack	of	 reliable	quantification	assays	 [88].	




used	 to	 interrogate	 the	 expression	 profile	 of	 INSL5	 cells	 and	 the	 hypothesis	 that	 GLP-1	
secretagogues	can	trigger	intracellular	Ca2+	responses	in	INSL5	cells.	Employment	of	LC/MS	
allowed	 quantification	 of	 INSL5	 secretory	 responses	 and	 also	 enabled	 simultaneous	
quantification	 of	 other	 peptide	 molecules	 including	 GLP-1	 and	 PYY.	 This	 allowed	 the	
hypothesis	 that	 INSL5	 is	 co-secreted	 with	 GLP-1	 and	 PYY	 in	 response	 to	 applied	 GLP-1	
secretagogues	to	be	tested.	Finally,	using	3D	structured	illumination	microscopy	(3D-SIM)	to	




1. To	 validate	 the	 novel	 INSL5	mouse	models	 Insl5-rtTA/TET-GFP	 and	 Insl5-rtTA/TET-	
GCaMP6FΔCMV	
2. To	compare	the	GPCR	repertoire	of	canonical	L-cells	with	that	of	INSL5	cells	
3. To	 examine	 intracellular	 Ca2+	 and	 INSL5	 secretory	 responses	 to	 known	 GLP-1	
secretagogues	
4. To	compare	the	secretory	response	profiles	of	INSL5,	GLP-1	and	PYY	








































to	 a	 drop	 in	 blood	 pressure	 and/or	 hyperosmolarity.	 AVP	 counteracts	 these	 homeostatic	
perturbations	 by	 increasing	water	 reabsorption	 from	 the	 kidneys	 and	 by	 vasoconstriction	
[215].		
	
In	 the	 same	 vein	 as	 angiotensin	 II,	 AVP	 appears	 to	 reduce	 net	water	 loss	 from	 the	 distal	
gastrointestinal	tract	via	stimulation	of	PYY	secretion.	In	vitro,	AVP	stimulated	GLP-1	and	PYY	
secretion	 from	murine	and	human	colonic	crypt	cultures	 inhibited	by	the	Avpr1b	 inhibitor	
SSR.	 Avpr1b	 expression	 is	 particularly	 enriched	 in	 colonic	 L-cells	 compared	 with	 small	
intestinal	 L-cells.	Avpr1b	 is	 a	 GPCR	which	 couples	 both	 to	 Gq	 and	Gs.	 This	 is	 reflected	 by	
observed	 L-cell	 elevations	 in	 intracellular	 Ca2+	 and	 cAMP	 levels	 upon	 AVP	 application.	 In	
healthy	human	participants,	serum	levels	of	copeptin	(a	stable	equimolar	biproduct	of	AVP	




























































labelling	 and	 electron	microscopy	 suggested	 co-storage	 between	 the	 two	 peptides	 [224].	
Habib	et	al.	also	found	overlap	between	the	GLP-1	and	PYY	vesicle	pool	in	human	colonic	crypt	
cultures	 using	 confocal	 microscopy	 [70].	 However,	 the	 resolving	 power	 of	 confocal	
microscopy	is	limited	around	the	diffraction	limit	of	200nm.	This	means	that	if	the	GLP-1	and	
PYY	vesicles	were	smaller	than	this	then	it	would	be	difficult	to	differentiate	close	together	








































































































Figure	 1:	 Verification	 of	 in	 vitro	 and	 in	 vivo	 induction	 of	 GFP/GCaMP6F	 expression	 by	

















for	 Insl5,	 Gcg	 and	 Pyy	 transcripts	 (figure	 2A).	 Insl5,	 Gcg	 and	 Pyy	 transcripts	 had	 relative	
expression	levels	712,	508	and	2052	fold	higher	in	the	GFP	positive	cells	than	in	the	control	
GFP-negative	 cell	 population	 (relative	 to	 ß-actin;	 fold	measurements	 based	 on	 geometric	


















Difference	 in	 cycle	 threshold	 (ΔCT)	 was	 evaluated	 between	 the	 gene	 of	 interest	 and	 the	




FACS	 output	 indicating	 sampled	 populations	 of	 GFP	 negative	 and	 positive	 cells.	 Figures	
adapted	from	Billing	et	al.	(2018)	[153].	
	













































































































Figure	 3:	 (A)	 Example	 of	 an	 immunofluorescently	 labelled	 INSL5	 cell	 which	 has	 been	
doxycycline	 induced	for	GCaMP6F	expression	 in	primary	culture	overnight.	Fixed	 in	4%	PFA	
and	 incubated	 with	 primary	 antibodies	 for	 INSL5	 (1:2000)	 and	 GFP	 (1:1000)	 respectively	
labelled	by	goat	secondary	antibodies	(1:300)	conjugated	to	AlexaFluor	488	and	647	followed	
by	treatment	with	Hoescht	nuclear	stain	(1:2000).	(B)	Representative	calcium	imaging	trace.	
(C)	 Fold	 changes	 in	 GCaMP6F	 fluorescence	 following	 addition	 of	 positive	 controls	 (10nM	





changes	 in	 fluorescence.	 Statistical	 significance	 assessed	 using	 a	Wilcoxon	 test.	 **p<0.01,	
***p<0.001.	Figure	adapted	from	Billing	et	al.	(2018)	[153].	











































































simultaneous	 INSL5	 and	 PYY	 release	 from	 murine	 crypt	 cultures	 (figure	 4A):	
forskolin/IBMX/glucose	(10µM/10µM/10mM),	arginine	vasopressin	(10nM),	AM-1638	(1µM),	
angiotensin	II	(10nM),	PMA	(1µM),	IBMX/glucose	(100µM/10mM),	GPBAR-A	(3µM),	SCFA	mix	
(3mM	 acetate,	 1mM	 butyrate	 and	 1mM	 propionate),	 bombesin	 (100nM),	 KCl	 (70mM),	 l-

















































































































































































































































































 The	majority	 of	 INSL5,	 GLP-1	 and	 PYY	 secretory	 vesicles	 label	 for	 all	
three	peptides	




surfaces	analysis	was	also	applied	 to	cultured	cells	 stained	with	a	 single	primary	antibody	
against	GLP-1	and	3	secondary	antibodies,	AlexaFluor	488,	555	and	633,	with	the	expectation	
that	 the	 three	 channels	would	 strongly	 overlap	 in	 3	 dimensions.	 However,	 the	 degree	 of	
R = 0.72





































































Figure	 6:	 Surfaces	 based	 analysis	 of	 immunofluorescently	 labelled	 murine	 colonic	 crypt	
cultures.	(A)	Representative	subsection	of	labelled	GLP-1,	PYY	and	INSL5	vesicles	imaged	using	
3D-SIM	and	rendered	in	3D	using	Imaris.	(B)	Mapped	vesicle	volume	occupied	by	labelled	GLP-
1,	 PYY	 and	 INSL5	 fractionated	 by	 single,	 dual	 and	 triple	 labelling.	 (C)	 Example	 image	 of	
surfaces	rendered	on	Imaris	from	the	individual	channels	for	GLP-1,	PYY	and	INSL5	shown	in	
A.	 (D)	 Surfaces	 rendered	 from	 identified	areas	of	 triple	 labelling	 from	C.	Analysis	of	GLP-1	
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633	 (the	same	samples	used	 to	examine	 the	surfaces	method)	>95%	of	 identified	vesicles	
































9C).	 The	 remaining	 cell	 however	 showed	 a	 different	 pattern	 with	 ~54%	 of	 vesicles	 triple	
labelled,	~10%	dual	 labelled	and	36%	single	 labelled	which	were	almost	all	GLP-1	 labelled	
(35.5%	GLP-1).	The	diameters	of	GLP-1	vesicles	labelled	with	AlexaFluor	488	(the	wavelength	
least	affected	by	chromatic	aberration)	were	205±92nm.	As	also	found	by	Cho	et	al.	(2014),	










below	 2%	were	 considered	 empty	 of	 that	 peptide.	 (C)	 Proportion	 of	 vesicles	 for	 each	 cell	
examined	which	were	single,	double	and	triple	labelled.	The	first	digit	of	the	y-axis	labels	refers	
to	 the	 particular	 crypt	 culture	 examined	 whilst	 the	 digits	 after	 the	 full	 stop	 refer	 to	 the	




















































The	 results	 of	 the	 intracellular	 calcium	 imaging	 experiments	 reflect	 the	 expression	 of	




Interestingly,	 past	 investigations	 found	 that	 peripheral	 administration	 of	 angiotensin-
converting	enzyme	 (ACE)	 inhibitors	 such	as	 captopril	 to	 fasted	 rats	decreased	 subsequent	






















and	 consequently	 added	 noise	 to	 observed	 intracellular	 Ca2+	 responses	 not	 observed	 in	
primary	 cultures.	 Chronic	 exposure	 of	 organoid	 derived	 L-cells	 to	 ENR	media	 (containing	
multiple	 different	 growth	 factors)	 could	 also	 have	 reduced	 the	 robustness	 of	 observed	
responses	 through	 downregulation	 of	 Gq-signalling	 pathways.	 Beyond	 differences	 in	 the	











The	 stimuli	 applied	 in	 the	 intracellular	 calcium	 imaging	 experiments,	which	 are	 known	 to	
trigger	GLP-1	and	PYY	secretion,	also	triggered	INSL5	secretion	implying	that	the	intracellular	
calcium	 transients	 elicited	 may	 couple	 to	 INSL5	 secretion	 (INSL5	 secretory	 responses	 to	
peptones	could	not	be	tested	as	the	mixture	of	peptides	would	obscure	the	LC/MS	output)	
[73–75,173,221].	Consistent	with	these	previous	studies,	LC/MS	analysis	confirmed	that	GLP-
1	and	PYY	were	also	 secreted.	The	murine	and	human	colonic	 crypt	 cultures	also	 showed	
largely	the	same	secretory	profiles	of	these	three	peptides.	These	results	imply	that	murine	





appear	 ~4	 times	 less	 responsive	 than	murine	 L-cells	 in	 terms	 of	GLP-1	 and	 PYY	 secretory	
responses	 [70].	Further	 refinement	of	 the	culture	conditions	and	 INSL5	peptide	extraction	
may	 therefore	help	 improve	 INSL5	detection	 for	 future	examinations	of	human	 INSL5	 cell	








stored	 in	 separate	 vesicle	 pools	 with	 a	 common	 release	 mechanism	 or	 stored	 together	
resulting	in	concomitant	secretion	upon	exocytosis.	Previous	findings	suggest	the	former,	as	
colonic	GLP-1	and	PYY	were	observed	in	separate	vesicles	in	some	studies	[87].	However,	our	









SIM	 techniques,	 they	used	 a	 volume	based	 approach	 to	 assess	 the	degree	of	 peptide	 co-
storage.	Using	similar	methods	we	similarly	found	a	high	percentage	of	single	labelled	vesicles	
in	primary	crypt	cultures,	albeit	considerably	less	than	found	by	Cho	et	al.	[230].	Application	
of	 this	 method	 to	 samples	 with	 triple	 labelled	 GLP-1	 illuminated	 a	 major	 flaw	 with	 this	
strategy.	The	three	channels	imaged	for	each	of	the	different	AlexaFluor	labels	used	should	
in	theory	overlap	exactly	and	as	such	one	would	expect	the	surfaces	analysis	to	reflect	this.	In	




appears	 to	 have	 occurred	 despite	 correction	 using	 fluorescent	 beads	 as	 the	 largest	
proportions	of	single	labelled	vesicular	volume	were	from	the	633nm	and	555nm	channels	
(figure	6H).	Our	new	methodology	overcame	these	issues	as	evidenced	by	the	>95%	overlap	
between	 the	 channels	 of	 the	 same	 GLP-1	 stained	 samples.	 GLP-1	 vesicles,	 labelled	 with	





GLP-1,	 PYY	 and	 INSL5	 vesicles	 were	 spherical	 in	 shape,	 with	 some	 (as	 seen	 in	 figure	 10)	





Whilst	L-cells	 immunofluorescently	 labelled	 from	crypt	cultures	and	 tissue	sections	 largely	
showed	the	same	proportions	of	triple,	dual	and	single	labelled	GLP-1,	PYY	and	INSL5	vesicles,	
there	 was	 slightly	 greater	 variation	 between	 L-cells	 analysed	 in	 the	 tissue	 sections	 than	
	 96	
primary	culture.	One	of	the	cells	in	a	fixed	section	had	36%	single	labelled	vesicles	which	were	
almost	 entirely	 GLP-1	 labelled.	 These	 variations	 may	 have	 resulted	 from	 variations	 in	
immunolabelling	 between	 different	 tissue	 sections,	 which	 exhibit	 greater	 background	
staining	than	primary	cultures.	It	should	be	noted	that	the	primary	antibodies	used	to	target	
GLP-1,	 PYY	 and	 INSL5	 likely	 exhibit	 differing	 detection	 limits	 which,	 despite	 protocol	
optimisation,	may	yield	underestimates	of	the	total	numbers	of	GLP-1,	PYY	and	INSL5	vesicles	




cells	 have	 been	 engineered	 to	 produce	 fluorescently	 tagged	GLP-1,	 PYY	 and	 INSL5	would	








the	 small	 and	 large	 intestines	 and	 INSL5	 limited	 to	 the	 large	 intestine	 [88,231].	 Post-
prandially,	acute	delivery	of	 the	nutrients	 to	 the	small	 intestine	 likely	 stimulates	L-cells	 to	
secrete	GLP-1	and	PYY	but	not	 INSL5,	exerting	a	net	anorexigenic	effect.	 In	the	 long	term,	
nutrients	 entering	 the	 colon	 and	 bacterial	 fermentation	 may	 stimulate	 INSL5	 secretion	
(together	with	GLP-1	and	PYY)	with	net	orexigenic	effects.	 It	 is	possible	that	the	combined	
action	of	 the	three	peptides	could	yield	different	effects	on	appetite	to	the	actions	of	 the	








enrichment	 of	 Gcg,	 Pyy	 and	 Insl5	 transcripts	 was	 found	 in	 cells	 expressing	 Rxfp4.	 The	
autoinhibitory	 nature	 of	 INSL5	 could	 be	 explored	 by	 application	 of	 a	modified	 version	 to	
murine	crypt	cultures	in	combination	with	a	stimulant	such	as	forskolin,	or	of	murine	INSL5	






by	 Cheryl	 Brighton).	 This	 suggests	 that	 INSL5	 can	 act	 as	 a	 paracrine	 modulator	 of	 5-HT	













In	 summary,	 INSL5	 cells	 express	 a	 range	 of	 known	 colonic	 L-cell	 GPCRs	 for	 physiological	
stimuli.	 Confirming	 my	 hypothesis	 that	 INSL5	 cells	 exhibit	 responses	 to	 known	 GLP-1	






1,	PYY	and	 INSL5	post-prandially	 likely	 reflect	 the	 regional	expression	profile	of	 Insl5	with	
activation	of	different	 L-cell	populations	along	 the	gastrointestinal	 tract.	 The	physiological	
significance	of	the	co-secretion	of	orexigenic	INSL5	with	anorexigenic	GLP-1	and	PYY	is	unclear	
but	we	postulate	that	INSL5	may	modulate	responses	to	GLP-1	and	PYY	potentially	acting	as	




























The	 diversity	 of	 EECs	 in	 the	 large	 intestine	 is	 lower	 than	 in	 upper	 regions	 of	 the	
gastrointestinal	 tract,	 predominantly	 consisting	 of	 5-HT-producing	 enterochromaffin	 cells,	
followed	 by	 L-cells	 and	 D-cells	 [238].	 The	 frequency	 of	 L-cells	 is	 particularly	 high	 when	
compared	with	the	rest	of	the	GI	tract	with	highest	abundance	in	the	rectum.	Roughly	50%	of	
these	 L-cells	 express	 Insl5	 [88].	 Whilst	 intracellular	 Ca2+	 and	 INSL5	 secretory	 responses	




RNA-seq	 (scRNA-seq)	 analysis.	 Furthermore,	 using	 a	 combination	 of	 RT-qPCR,	

































L-cells	 are	 the	 second	most	 abundant	 type	 of	 EEC	 in	 the	 colon	with	 increasing	 frequency	
moving	 through	 the	 proximal-distal	 axis	 [238].	 Roughly	 half	 of	 the	 total	 colonic	 L-cell	
population	express	Insl5	[88].	Immunohistochemistry	experiments	in	mouse	have	shown	that	
the	number	of	INSL5-positive	cells	increases	moving	from	the	caecum	down	to	the	rectum.	









primary	 cultures	 display	 smaller	 GLP-1	 secretory	 responses	 to	 glucose	 and	 to	 the	 non-
metabolisable	glucose	analogue	α-methylglucopyranoside	(transported	by	SGLT1)	than	small	
intestinal	 primary	 cultures	 [59].	 Furthermore,	 in	 in	 vivo	 experiments	 using	 mice,	 direct	
intraluminal	 application	 of	 glucose	 to	 the	 colon	 did	 not	 trigger	 increased	 plasma	 GLP-1	
whereas	 intraluminal	 application	 of	 glucose	 to	 the	 small	 intestine	 did	 [244].	 Likewise,	 no	
significant	increase	in	GLP-1	secretion	was	measured	from	human	colonic	primary	cultures	to	
glucose	application	 [245].	Contrastingly,	Agtr1a	 and	Avpr1b,	 genes	encoding	 receptors	 for	
angiotensin	II	and	AVP	respectively,	are	highly	enriched	in	murine	colonic	L-cells	compared	
with	 small	 intestinal	 L-cells	 [73,74].	 These	 results	 provide	 further	 evidence	 for	 regional	
differences	in	nutrient	sensing	by	intestinal	L-cells.	scRNA-seq	analysis	of	the	total	colonic	EEC	















As	 in	other	 regions	of	 the	gastrointestinal	 tract,	 somatostatin	 acts	 as	 a	 global	 inhibitor	of	
















Unlike	 bulk	 RNA-seq,	whereby	 transcriptomes	of	 entire	 cell	 populations	 are	 analysed	 and	
compared,	single	cell	RNA-seq	(scRNA-seq)	enables	the	examination	of	the	transcriptome	of	
each	 individual	 cell	 within	 a	 cell	 population.	 Cluster	 analysis	 of	 these	 individual	
transcriptomes	 in	 turn	 enables	 identification	 of	 cellular	 subgroups	 within	 the	 analysed	
population.	Currently	scRNA-seq	techniques	depend	on	separation	of	cells	either	by	FACS	into	
individual	wells	 on	 a	 plate,	microfluidics	 or	 encapsulation	 into	 separate	 reaction	 droplets	














murine	 duodenum	 [64].	 Analysis	 of	 transcriptomic	 profiles	 of	 FACS-isolated	 cells	 from	
duodenal	 digests	 generated	 from	 Glu-venus	 mice	 identified	 3	 main	 subgroups.	 The	
predominant	group	(51%)	was	highly	enriched	for	Gcg	and	Pyy	transcripts,	the	second	most	
abundant	 (35%)	was	 identifiable	by	Tph1	 and	Pzp	 enrichment	whilst	 the	 remaining	 group	
(14%	 total)	 was	 particularly	 enriched	 for	Gip	 transcripts.	 These	 results	 imply	 that	 in	 the	
proximal	small	intestine	alongside	the	classical	L-cells,	which	express	high	levels	of	Gcg	and	
Pyy,	a	small	percentage	of	L-cells	overlap	with	K-cells	and	the	remainder	appear	to	overlap	












FACS-isolated	 based	 on	 expression	 of	 the	 mature	 enteroendocrine	 cell	 marker	 NeuroD1	
[139].	 For	 this	 purpose,	 single	 cell	 digests	 were	 prepared	 from	 a	 whole	 colon	 (from	 the	
caecocolic	 junction	to	the	end	of	 the	rectum)	extracted	from	a	NeuroD1-EYFP	mouse	(see	
methods).	The	Chromium	platform	was	chosen	over	plate-based	methods	because	it	allows	
high	 throughput	 analysis	 of	 1000s	 cells	 at	 an	 affordable	 cost	 per	 cell	 screened	 and	 we	
hypothesised	 that	 the	 main	 EEC	 subdivisions	 would	 be	 identifiable	 by	 genes	 with	 high	
transcript	abundance,	such	as	hormones	and	enzymes,	which	are	readily	detectable	by	drop-












































genes	 of	 the	 INSL5	 and	 NTS	 L-cells	 together	 with	 the	 secretin,	 Tac1	 and	 piezo2	 EC	 cell	
subgroups,	D-cells	and	goblet	cells.	The	top	10	differentially	expressed	genes	were	identified	



























































































INSL5	cells.	On	the	other	hand,	cluster	8	was	enriched	for	Nts	expression	and	 low	 in	 Insl5	
expression	and	are	referred	to	as	NTS	cells.	385	of	665	cells	(~58%)	L-cells	fell	into	the	INSL5	
cell	 subgroup	 roughly	 consistent	 with	 previous	 data	 implying	 half	 the	 colorectal	 L-cell	
population	 are	 INSL5	 producing	 [88].	 Beyond	 differential	 expression	 of	 Insl5	and	Nts,	 the	
INSL5	cells	are	distinguishable	by	enrichment	in	transcripts	for	various	gut	associated	peptides	











with	Nts	 (R=0.093;	 figure	3E),	Pyy	was	negatively	 correlated	with	Nts	 (R=-0.29;	 figure	3F).	











R=-0.46, p=<2.2e-16 R=-0.15, p=0.00017
R=0.55, p=<2.2e-16












Tac1	 and	 Reg4	 transcripts	 (figure	 2).	 Transcripts	 of	 Tac1	 encode	 for	 tachykinin	 peptide	
precursors,	including	substance	P	and	have	been	previously	been	linked	with	EC	cells.	A	subset	
of	these	Tac1-expressing	EC	cells	were	found	to	express	high	levels	of	Reg4	in	other	scRNA-
seq	 based	 studies	 [65].	 Immunohistological	 examinations	 of	 serotonin,	 secretin	 and	






distinguished	by	 selective	 enriched	expression	of	 the	 transcription	 factor	Hoxb13	 and	 the	
mechanosensitive	 ion	channel	Piezo2	(figure	2).	As	previously	discussed,	some	EC	cells	are	
mechanosensitive	and	regulate	gastrointestinal	motility	through	5-HT	release.	Recent	Ussing	














identifies	 them	 as	 D-cells.	 These	 cells	 are	 also	 distinguishable	 by	 expression	 of	 the	
transcription	factors	Isl1	and	Hhex	(figure	2).	Consistent	with	this	selective	enrichment,	Isl1	
expression	 has	 previously	 been	 identified	 as	 specific	 to	 mature	 D-cells	 in	 the	 murine	









and	 is	 therefore	another	marker	of	 intestinal	goblet	cells	 [259].	 	 Likewise,	goblet	cells	are	

























and	 Avpr1b	 the	 cognate	 receptors	 for	 angiotensin	 II	 and	 arginine	 vasopressin	 (AVP)	
respectively	(figure	4).	Functional	expression	of	these	receptors	in	Insl5-expressing	L-cells	was	





over	 the	 other	 L-cell	 subgroups	 (figure	 4)	 [262–264].	 Previous	 RT-qPCR	 and	
immunohistological	based	studies	indicate	that	Olfr78	is	restricted	to	the	colon	of	mice	and	
overlaps	with	GLP-1	and	PYY	labelling	with	increased	numbers	of	labelled	Olfr78	cells	moving	
distally	 along	 the	 colon.	 Together	with	 evidence	 that	 co-labelling	 of	 Olfr78	with	 PYY	was	
greater	than	with	GLP-1	(35%	of	PYY-labelled	cells	vs.	17%	of	GLP-1	labelled	cells),	the	findings	
are	 consistent	 with	 selective	 expression	 of	 Olfr78	 in	 Insl5-expressing	 L-cells	 which	 are	
enriched	for	Pyy	over	Gcg	expression	[262].	Regarding	Galr1,	functional	expression	of	Galr1	
has	been	 identified	 in	L-cells	of	the	murine	small	and	 large	 intestine	and	has	an	 inhibitory	


















GPCRs	 transcripts	 differentially	 abundant	 in	 Nts-expressing	 L-cells	 compared	 with	 Insl5-
expressing	L-cells	include	those	for	Gpr27	and	Sucnr1	(figure	4).	The	orphan	GPCR	GPR27	is	a	
poorly	characterised	Gq-coupled	receptor	but	appears	to	modulate	glucose-stimulated	insulin	
secretion	 from	 beta-cells	 since	 knockdown	 of	 Gpr27	 significantly	 attenuated	 glucose-
stimulated	 insulin	 secretion	 from	 isolated	murine	 islets	 [266].	 Likewise,	 glucose-tolerance	
tests	applied	 in	murine	knockout	studies	of	Sucnr1	 (encoding	the	preferentially	Gi-coupled	
succinate	 receptor	 1	 –	 SUCNR1)	 suggest	 that	 SUCNR1	 is	 a	modulator	 of	 insulin	 secretion	






receptor	 and	 Adora2a	 which	 encodes	 the	 Gs-coupled	 adenosine	 A2A	 receptor	 [269,270].	






Examination	 of	 differentially	 expressed	 GPCRs	 in	 Tac1-expressing	 cells	 found	 limited	
differences.	These	differences	include	Olfr78	and	Olfr558	(figure	4).	Previous	RT-qPCR	analysis	
of	FACS-isolated	colonic	EC	cells	revealed	enrichment	for	both	genes	with	~640	fold	higher	
levels	 of	Olfr78	 than	Olfr558	 [240].	 Our	 results	 appear	 to	 reflect	 these	 findings	 as	Olfr78	
expression	was	higher	in	Tac1-expressing	cells	than	Olfr558	and	unlike	Olfr558,	Olfr78	was	
















findings	 are	mixed	with	one	 study	 indicating	 that	 intravenously	 delivered	VIP	may	 trigger	




differential	 5-HT	 secretory	 effects	 on	 the	 Sct	 and	Piezo2-expressing	 subgroups.	 However,	












form	a	 functional	 receptor	 for	CGRP	 in	colonic	D-cells.	Correspondingly,	Calcrl	and	Ramp1	











The	 purinergic	 receptors	 P2ry1	 and	 P2ry14	 appear	 to	 be	 enriched	 these	 cells	 (figure	 4).	








other	 genes	 such	 as	Nts	which	had	 a	 low	abundance	of	 transcripts	 specifically	 in	 clusters	
enriched	 for	 INSL5	 transcripts	when	 compared	with	other	 L-cell	 subgroups.	We	 sought	 to	




Relative	expression	 (2∆CT,	 +SEM,	 -SEM)	of	 the	peptides	Ppy	and	Nts	was	0.199	 (+0.0902,	 -
0.0836)	and	0.0383	(+0.0319,	-0.0309)	respectively,	reflecting	a	93.2	and	58.5	fold	enrichment	
in	 the	 INSL5	 cells	 compared	 with	 control	 cells.	 Likewise,	 relative	 expression	 of	 the	 SCFA	
receptor	Olfr78	 and	 the	 SCFA	 transporter	Slc5a8	 (see	 appendix	 2)	was	0.0478	 (+0.0276,	 -







by	 FACS-purified	 INSL5	 cells	 (n=3	mice).	 Difference	 in	 cycle	 threshold	 (ΔCT)	was	 evaluated	
between	the	gene	of	interest	and	the	housekeeper	β-actin.	These	values	were	used	to	derive	
relative	expression	as	2ΔCT.	Bars	represent	mean	relative	expression	with	error	bars	reflecting	














Relative	 expression	 of	 Insl5	 was	 highest	 in	 the	 distal	 segments	 of	 colon	 (P4-P7)	 with	



































cells	 and	 EC	 cells	 respectively,	 was	 examined	 (figure	 6B).	 Sst	 expression	 was	 reasonably	
consistent	across	 the	 length	of	 the	colon	though	 in	P7	expression	 levels	were	significantly	












expressed	 within	 all	 colonic	 L-cell	 subpopulations)	 or	 that	 of	 Calcrl	 (specifically	 enriched	













significant	 deviations	 in	 cycle	 threshold	differences	 from	values	 in	 P1	were	assessed	using	


























































































































































































crypt	cultures,	murine	colons	were	subdivided	 into	proximal	 (P1-P2),	 intermediate	 (P3-P5)	







increasing	 levels	 of	 INSL5	 moving	 along	 the	 proximal-distal	 axis.	 Basal	 INSL5	 levels	 were	
significantly	~21	and	~29	times	higher	in	the	intermediate	and	distal	colon,	respectively,	than	
in	 the	 proximal	 colon.	 Showing	 a	 reverse	 of	 this	 trend,	 basal	 NTS	 levels,	 though	 not	








levels	 of	 NTS	 measured	 following	 AM-1638	 administration	 to	 proximal	 and	 intermediate	
colon	relative	to	basal.	Differences	in	NTS	responses	to	AM-1638	between	the	proximal	and	




On	the	other	hand,	AM-1638	triggered	significant	 responses	 to	PYY	across	all	 regions	 that	
	 122	




NTS	 responses	 were	measured	 to	 angiotensin	 II	 application	 in	 any	 region.	 INSL5	 did	 not	
display	significant	responses	to	angiotensin	II	in	the	intermediate	or	distal	colon	(levels	in	the	
proximal	 colon	 were	 undetectable)	 when	 compared	 to	 basal	 secretion	 though	 levels	
measured	 from	 distal	 colon	 were	 significantly	 higher	 than	 from	 intermediate	 colon.	 PYY	














































































































































protein	 content	 for	 each	 well	 measured	 through	 a	 BCA	 assay.	 Statistically	 significant	
responses	 (#p<0.05)	 to	 a	 particular	 stimulus	 were	 assessed	 through	 comparison	 to	 basal	
responses	 in	 each	 region	 using	 one-way	 ANOVA	 tests	 on	 square	 root	 transformed	 data.	




mice	with	 test	 conditions	 run	 in	duplicate	on	each	plate.	N=	4	 independent	wells	with	 the	
following	exceptions:	n=3	for	proximal	NTS	responses	to	angiotensin	 II;	n=2	for	 INSL5	from	
proximal	colon	and	intermediate	colon	for	NTS	in	the	basal	condition	together	with	PYY	from	












NTS	 has	 previously	 been	 identified	 in	 intestinal	 L-cells	 (by	 immunohistochemistry	 and	
expression	 analysis)	 and	 is	 co-released	 with	 GLP-1	 and	 PYY	 exerting	 anorexigenic	 effects	
[101,239].	In	accordance,	Ratner	et	al.	suggest	that	(from	in	vivo	experiments	with	rats	using	
NTS	 receptor	 antagonists)	 part	 of	 the	 weight	 loss	 following	 RYGB	 results	 from	 increased	
plasma	NTS	[105].	With	respect	to	the	colon,	NTS	has	been	 linked	to	colitis	and	colorectal	





proximal	part	of	 the	colon	whilst	 Insl5	 expression	 (in	accordance	with	previous	 studies)	 is	
concentrated	 in	 the	distal	colon	 [88].	Meanwhile,	Pyy	expression	was	 relatively	consistent	
between	 colonic	 segments	 but	Gcg	 expression	was	 lower	 in	more	 distal	 segments	 [282].	
Furthermore,	Cck	expression	was	lowest	in	the	most	distal	segments	of	colon	consistent	with	
a	previous	examination	of	regional	expression	and	consistent	with	a	drop	in	Nts-expressing	L-
cells	 (Cck	 expression	 was	 enriched	 in	 Nts-expressing	 L-cells	 –	 see	 appendix	 1)	 	 [282].	
Consistently,	 previous	 investigations	 by	 Fakhry	 et	 al.	 (2017)	 found	 that	 Cck	 expression	
dropped	moving	from	proximal	to	distal	colon	 in	mouse.	Furthermore	Fakhry	et	al.	 (2017)	
using	immunostaining	and	peptidomic	analysis	detected	low	levels	of	bioactive	CCK	peptides	
in	 the	colon	and	that	CCK	 labelled	cells	often	co-stained	 for	PYY	suggesting	 that	 the	L-cell	
enrichment	 for	 CCK	 transcripts	 identified	 in	 the	 scRNA-seq	 analysis	 here	 may	 reflect	












is	 important	 to	note	 that	 the	accuracy	of	 the	 cell	 counts	depend	on	 the	 sensitivity	of	 the	
antibodies	used	to	their	respective	antigens.	For	example,	the	low	number	of	NTS	labelled	



















abundance	 for	 a	 particular	 gene	 with	 large	 variations	 in	 translational	 efficiency	 between	





Regarding	 identification	 of	 enteroendocrine	 peptides	 other	 than	 GLP-1,	 PYY	 and	 INSL5	
produced	by	 Insl5-expressing	L-cells,	the	scRNA-seq	analysis	highlights	secretogranin	2	and	
pancreatic	polypeptide	as	potential	candidates.	Secretoneurin,	the	active	peptide	derivative	
of	 secretogranin	 2,	 has	 been	 implicated	 in	 a	 diverse	 range	 of	 physiological	 functions	
throughout	 the	 body,	 including	 regulation	 of	 reproductive	 processes,	 angiogenesis	 and	 in	
inflammation	and	has	been	measured	in	the	rat	intestine	by	radioimmunoassays	[286,287].	
Hypothalamic	 expression	 of	 Scg2	 increases	 after	 a	 24-hour	 fast	 in	 mice	 suggesting	
involvement	 in	 appetite	 regulation.	 In	 fact,	 secretogranin	 2	 mediates	 accumulation	 of	






The	 other	 candidate	 peptide,	 pancreatic	 polypeptide	 (PP)	 is	 predominantly	 produced	 and	
released	from	PP	cells	of	the	pancreatic	islets	but	rare	numbers	of	PP-producing	cells	have	
been	detected,	by	immunohistochemistry,	in	the	human	colon	and	rectum	[67].	Interestingly	
the	 intestinal	 PP	 cells	 do	 not	 appear	 to	 produce	 PYY	 and	 could	 comprise	 some	 of	 the	
immunofluorescently	labelled	INSL5	cells	we	observed	in	murine	colon	wholemounts	that	did	
not	 overlap	 with	 PYY	 [289].	 Regarding	 function,	 PP	 has	 an	 anorexigenic	 effect	 when	
administered	 in	vivo	or	overexpressed	[252].	Physiologically,	PP	release	has	a	cephalic	and	








Regarding	 the	 relevance	 of	 these	 murine	 findings	 to	 human	 physiology,	 whilst	 INSL5-
producing	L-cells	are	found	in	the	large	intestines	of	both	humans	and	mice,	in	humans	NTS-
producing	cells	are	largely	restricted	to	the	jejenum	and	are	scarce	(1	per	100	crypts)	in	the	
large	 intestine	 [98,99,104].	 This	 suggests	 that	 in	 humans	 the	 non-INSL5	producing	 L-cells,	





further	 study	 using	 human	 tissue,	 including	 secretion	 assays,	 should	 help	 clarify	 the	
physiological	relevance	of	murine	colonic	NTS-producing	L-cells.	
	































highest	 in	 the	 proximal	 colon	 and	 undetectable	 in	 the	 distal	 colon	 whilst	 INSL5	 levels	
increased	moving	from	the	proximal	to	distal	colon	and	PYY	levels	did	not	significantly	vary	
between	regions.	Similar	regional	differences	of	the	NTS,	INSL5	and	PYY	secretory	responses	
to	AM-1638	and	 the	positive	control	10mM	glucose	+	 IBMX	were	observed.	On	 the	other	
hand,	application	of	angiotensin	 II	appeared	to	trigger	 INSL5	and	PYY	responses	only	from	
distal	 crypt	 cultures	 and	 not	 from	 any	 region	 for	 NTS.	 Consistently,	 no	 significant	 NTS	
responses	 were	 measured	 in	 secretions	 from	 whole	 colon	 generated	 crypt	 cultures	 to	
angiotensin	II	(or	 indeed	AVP)	application	whereas	INSL5,	GLP-1	and	PYY	were	co-secreted	
(unpublished	data	from	Pierre	Larraufie).	Combined	with	the	scRNA-seq	and	RT-qPCR	data	
these	 results	 imply	 specific	 functional	 expression	 of	 Agtr1a	 in	 Insl5-expressing	 over	Nts-
expressing	L-cells	and	non-specific	L-cell	expression	of	Ffar1.	Thus,	the	Insl5-expressing	and	
Nts-expressing	 L-cell	 subsets	 are	 not	 simply	 distinguished	 by	 differential	 EEC	 peptide	
expression	and	production	but	also	functional	GPCR	expression.	
	















the	plate-based	SMART-seq2	platform.	For	example,	 in	 the	 context	of	 L-cells	 SMART-seq2	




 Colonic	 enterochromaffin	 cells	 comprise	 of	 three	 subpopulations	
marked	by	Sct,	Tac1	and	Piezo2	expression	








not	 clear.	 Clarification	 could	 be	 obtained	 through	 mass	 spectrometry	 analysis	 of	 colonic	
sample	peptide	content	together	with	immunofluorescent	experiments.	It	should	be	noted	
that	whilst	Lund	et	al.	(2018)	identified	Sct	expression	in	small	intestinal	EC	cells,	they	did	not	
detect	Sct	 expression	 in	 colonic	 EC	 cells	 [240].	 Expression	of	 the	NPY/PYY	 receptor	Npy1r	








P,	 derived	 downstream	 of	 Tac1	 expression,	 from	 these	 cells	 which	 is	 a	 known	
proinflammatory	 peptide.	 It	 is	 known	 to	 trigger	 cytokine	 production	 and	 release,	 local	
vasodilation	and	algesia	and	even	possesses	antimicrobial	properties	[299–302].	With	regards	
to	 the	 intestine,	 substance	P	has	been	 implicated	 in	 intestinal	 inflammation	with	possible	
significance	 to	 the	 pathphysiology	 of	 IBD	 and	 as	 a	 regulator	 of	 circular	 smooth	 muscle	
contractions	in	human	colon	[303–305].	Therefore,	in	addition	to	potential	mediation	of	local	
inflammatory	 responses,	 substance	 P	 release	 may	 represent	 an	 additional	 means	 of	
modulating	colonic	contractility	to	5-HT	release	in	Tac1-expressing	cells	when	compared	with	
the	other	EC	subgroups.	Together	our	findings	imply	that	further	study	of	this	subgroup	of	
Tac1-expressing	 EC	 cells,	 particularly	 regarding	 differential	 stimulation	 from	 the	 other	 EC	





around	 the	 distal	 crypt	 (i.e.	 closest	 to	 the	 lumen)	 and	 Tac1-expressing	 EC	 cells	 clustered	
around	the	base	of	the	crypt	[132].	In	crypts	of	both	the	small	and	large	intestines,	EECs	(along	
with	 enterocytes/coloncytes	 and	 other	 secretory	 cell	 types)	 are	 derived	 from	 stem	 cells	
located	at	the	base	of	the	crypt.	These	stem	cells	function	to	replenish	epithelial	cells	shed	






expressing	 EC	 cells	 as	 they	mature	 and	move	 upwards	 along	 the	 crypt	 axis	 (towards	 the	




Similarly,	 Nts	 expression	 was	 found	 to	 be	 upregulated	 whilst	 expression	 of	 Gcg	 was	
downregulated	 by	 BMP	 signalling	 by	 Beumer	 et	 al.	 (2018)	 supporting	 previous	
immunohistological	 and	 transcriptomic	 investigations	 by	 Grunddal	 et	 al.	 (2016)	 indicating	
that	 NTS	 cells	 were	 concentrated	 in	 the	 distal	 crypt	 whilst	 GLP-1	 producing	 cells	 were	
concentrated	at	the	crypt	base.	Furthermore,	 in	the	Grunddal	et	al.	 (2016)	study	selective	
ablation	 of	 L-cells	 (via	 diphtheria	 toxin	 administration	 to	 transgenic	 mice	 engineered	 to	
express	of	human	diphtheria	toxin	receptor	under	the	proglucagon	promoter)	revealed	that	





et	 al.	 (2016)	 studies	 investigated	 small	 intestinal	 EECs	 and	 that	 these	 findings	might	 not	
translate	well	to	colonic	crypts.	Indeed,	given	that	Pyy	expression	was	negatively	correlated	





Piezo2	 is	 a	 non-selective	 cationic	 channel	 which	 is	 mechanosensitive,	 meaning	 that	











expressing	 EC	 cells	might	 be	 concentrated	 in	 the	 proximal	 colon.	 No	 similar	 analysis	was	
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other	 regions	of	 the	 gastrointestinal	 tract.	 For	 example,	 colonic	D-cells	were	 enriched	 for	
Iapp,	Calcrl	 and	Adra2a	 transcripts,	genes	which	are	also	expressed	 in	gastric	D-cells.	This	
suggests	 that	 intestinal	 D-cells	 may	 not	 display	 regional	 differences	 in	 expression	































into	 subgroups.	 L-cells	 divided	 into	 two	 main	 groups	 consisting	 of	 distally	 located	 Insl5-
expressing	and	proximally	 located	Nts-expressing	cells	with	 functional	differences	 in	GPCR	
repertoire.	Meanwhile	EC	cells	divided	into	three	groups	distinguished	by	expression	of	Sct,	
Tac1	and	Piezo2.	We	postulate	that	the	Tac1	and	Piezo2	groups	may	reflect	pro-inflammatory	


















In	 chapter	 3,	 concomitant	GPBAR-1	 activation	was	 found	 to	 potentiate	 L-cell	 intracellular	
calcium	 responses	 to	 FFAR1	 activation	 and	 30mM	 KCl	 application.	 Likewise,	 GPBAR-1	
activation	 potentiated	 FFAR1-mediated	 GLP-1	 secretion.	 This	 suggests	 coupling	 of	 the	
potentiated	intracellular	calcium	responses	observed	to	increased	GLP-1	secretion	(since	GLP-
1	 secretion	 is	 calcium	 dependent).	 These	 findings	 were	 achieved	 using	 small	 intestinal	
organoids	which	appear	to	recapitulate	native	L-cell	physiology.	Further	application	of	these	
small	 intestinal	 organoids	 in	 secretion	 and	 electrophysiological	 experiments	 suggests	
involvement	of	TRPC3	and	L-type	VGCCs	in	the	synergy	seen	between	the	GPBAR-1	and	FFAR1	













modification.	 	 Pharmacological	 experiments	 could	 examine	 PKA-independent	 effects	 of	
GPBAR-1	 stimulation	 through	 the	 cAMP	 effector	 EPAC2	 by	 applying	 the	 EPAC2	 selective	
antagonist	ESI-05	in	intracellular	calcium	and	secretion	assays	[309].	Likewise,	 inhibition	of	
PKC	using	sphingosine	could	identify	potential	involvement	of	PKC	[310].	Concerning	genetic	





channel	 agonist	 Bayk8644	 [203].	 Future	 experiments	 should	 also	 establish	 the	 clinical	








these	 GPCRs,	 was	 confirmed	 by	 intracellular	 calcium	 transients	 elicited	 upon	 specific	
pharmacological	 activation.	 Consistently,	 stimulation	 of	 these	 GPCRs	 along	 with	 other	
previously	characterised	L-cell	GPCRs	stimulated	INSL5	release	from	both	murine	and	human	
crypt	 cultures.	 The	 use	 of	 LC/MS	 peptide	 quantification	 enabled	 INSL5	 secretion	 to	 be	





populations	 of	 GLP-1,	 PYY	 and	 INSL5	 secretory	 vesicles	 regulated	 by	 a	 common	 release	
mechanism.	 This	 hypothesis	 was	 explored	 in	 chapter	 4	 by	 3D-SIM	 analysis	 of	
immunofluorescently	labelled	primary	cultures	and	sections	of	murine	colonic	tissue.	Overlap	
between	 identified	GLP-1,	 PYY	 and	 INSL5	 vesicles	within	 imaged	 L-cells	was	 examined	 by	










(2014)	 used	 an	 approach	 (dubbed	 the	 surfaces	 analysis)	which	 examined	 volume	 overlap	
between	vesicles	rendered	in	3D	using	Imaris	(Bitplane).	Applying	a	similar	approach	to	our	
data	 indicated	roughly	50%	of	vesicles	were	single	 labelled	 for	GLP-1,	PYY	and	 INSL5.	One	
potential	 concern	 with	 the	 surfaces	 analysis	 was	 under-representation	 of	 dual	 or	 triple	
labelled	 vesicles	 due	 to	 differences	 in	 the	 excitation	 wavelengths	 of	 the	 fluorophores	
conjugated	 to	 the	 secondary	antibodies	used.	We	hypothesised	 that	 the	 surfaces	method	
would	 yield	 different	 vesicle	 size	 estimates	 when	 labelled	 with	 fluorophores	 with	 long	









significance	 of	 simultaneous	 GLP-1,	 PYY	 and	 INSL5	 secretion	 on	 food	 intake	 regulation	 is	
unclear	[88,211,212].	One	could	hypothesise	that	the	restriction	of	INSL5-producing	L-cells	to	










 Murine	 colonic	 L-cells	 divide	 into	 Insl5-expressing	 and	Nts-expressing	
cells	
scRNA-seq	 analysis	 of	 colonic	 enteroendocrine	 cells	 in	 chapter	 5	 enabled	 further	




showed	 the	 converse	 relationship	 to	Pyy	 expression	with	highest	 expression	 found	 in	 the	
Insl5-expressing	L-cells.	Additionally,	the	two	subsets	appear	to	differentially	express	other	
appetite	 regulating	 peptides	 with	 a	 subset	 of	 Insl5-expressing	 cells	 enriched	 for	 Ppy	
expression	 whilst	 Nts-expressing	 cells	 were	 enriched	 for	 Cck	 expression	 [92,252].	 These	






of	 the	 identified	 NTS-producing	 L-cells	 to	 human	 physiology	 is	 unclear,	 since,	 unlike	 in	
rodents,	 Nts	 is	 scarcely	 found	 in	 the	 human	 large	 intestine	 (figure	 1)	 [97–99].	 However,	
colonic	murine	Nts-expressing	L-cells	may	act	as	a	useful	model	for	a	known	subset	of	human	






Figure	1:	Heatmap	representation	of	gut	hormones	across	 the	gastrointestinal	 tract	of	 (A)	







cells	 distinguished	 by	 Sct,	Tac1	 or	Piezo2	expression.	 The	Sct-expressing	 EC	 cell	 subgroup	
differentially	express	the	PYY	activated	receptor	Npy1r	potentially	reflecting	regulation	of	this	
subpopulation	by	L-cell	 secretions	 [269].	This	 is	consistent	with	 recent	 findings	 that	GLP-1	
stimulates	5-HT	secretion	from	intestinal	ECs.	Interestingly,	the	same	study	found	expression	





downstream	 of	 Tac1	 expression	 [299].	 Accordingly,	 Tac1	 expression	 and	 substance	 P	






























all	 regions,	 INSL5	 from	 distal	 colon	 and	 NTS	 from	 proximal	 colon.	 The	 peptide	 secretion	
profiles	 resulting	 from	FFAR1	activation	are	consistent	with	previous	results	 in	which	NTS,	
GLP-1	and	PYY	were	co-secreted	in	response	to	AM-5262	(FFAR1	agonist)	application	from	
small	 intestinal	 and	 colonic	 crypt	 cultures	 [101].	 Together	 the	 secretion	 results	 support	
functional	 differences	 in	 the	 proximal-distal	 colonic	 distribution	 and	 GPCR	 repertoires	 of	
INSL5	and	NTS-producing	L-cells.	
	
Regarding	 GPCRs	 differentially	 expressed	 in	 the	 other	 EECs	 subgroups,	 as	 previously	
mentioned,	Sct-expressing	EC	cells	express	Npy1r	potentially	reflecting	L-cell	regulation	of	this	
subset	 of	 EC	 cells.	 Tac1-expressing	 EC	 cells	 were	 enriched	 with	 transcripts	 for	 the	 SCFA	
receptor	Olfr78	consistent	with	findings	by	Lund	et	al.	(2018)	and	suggests	that	this	subset	of	
EC	cells	responds	to	the	bacterial	microbiota	[240].	Olfr78	was	also	highly	enriched	within	
Insl5-expressing	 (but	 not	 in	 Nts-expressing)	 L-cells	 which	 probably	 reflects	 previous	
















suggesting	 that	 INSL5	 is	 orexigenic,	 potentiates	 glucose-stimulated	 insulin	 secretion	 and	
modulates	hepatic	glucose	production	[88,90,91].	In	part,	these	studies	have	been	hampered	
by	unreliable	INSL5	quantification	using	current	 immunoassays	[311].	The	LC-MS	approach	
presented	 in	 this	 thesis	 presents	 a	 solution	 to	 this	 long-running	 issue.	 Members	 of	 the	



















Rxfp4-cre/Rosa26-RFP	 mice	 was	 carried	 out	 by	 Cheryl	 Brighton	 (unpublished	 data).	 This	





from	Rxfp4-cre/Rosa26-EYFP	mice.	 This	 profile	 of	 Rxfp4	 labelling	 suggests	 that	 INSL5	may	
autoinhibit	 a	 subset	 of	 L-cells	 (through	 Gi-coupled	 signalling),	 regulate	 gastrointestinal	
motility	 (through	 modulation	 of	 EC	 cells)	 and	 modulate	 activities	 of	 the	 enteric	 nervous	
system.	However,	 it	 should	be	noted	 that	 levels	of	Rxfp4	 transcripts	detected	by	RT-qPCR	
were	very	low	or	undetectable	in	FACS-purified	L-cells	and	nodose	ganglia	(unpublished	data	
from	Cheryl	Brighton).	This	discrepancy	likely	reflects	historical	and	transient	expression	of	





Building	 on	 the	 results	 from	 chapter	 5,	 future	 experiments	 could	 attempt	 to	 selectively	
stimulate/inhibit	 specific	 subsets	 of	 EECs	 with	 secretory	 responses	 quantified	 by	 LC/MS	
analysis.	For	example,	the	scRNA-seq	analysis	indicates	that	subunits	of	the	CGRP	receptor	
are	specifically	expressed	in	D-cells.	This	suggests	that	selective	secretion	of	SST-28	might	be	
achieved	 by	 CGRP	 application.	 Furthermore,	 enrichment	 of	Galr1,	 the	 Gi-coupled	 galinin	
receptor	 mRNA,	 in	 Insl5-expressing	 over	 Nts-expressing	 L-cells	 suggests	 that	 selective	
inhibition	of	INSL5	secretion	might	be	achievable	[264].	Given	the	orexigenic	effects	of	INSL5,	
suppression	of	 INSL5	secretion	may	yield	therapeutic	benefits	 to	obese	patients.	Likewise,	
selective	 stimulation	of	non-INSL5	producing	 L-cells	may	prove	advantageous	 through	 the	
stimulated	release	of	anorexigenic	GLP-1	and	PYY	without	release	of	orexigenic	INSL5.	To	this	






sensitive	 scRNA-seq	 techniques	 such	 as	 SMART-seq2	 could	 therefore	 enable	 detection	 of	
further	differences	in	GPCR	repertoire	between	different	EEC	subtypes.	For	example,	FACS-





differentiated	 intestinal	 organoids	 could	 be	 analysed.	 By	 using	 intestinal	 organoids	 rather	
than	 primary	 tissue	 for	 scRNA-seq	 analysis,	 the	 transcriptomes	 of	 epithelial	 cells	 can	 be	
isolated	without	contamination	with	other	cell	 types	e.g.	 smooth	muscle	cells	and	enteric	
neurons	 [65].	 To	 enhance	 this	 approach,	 fluorescent	 tags	 expressed	 under	 the	 control	 of	
specific	 cell-type	markers	 (e.g.	NeuroD1	 for	EECs)	could	be	knocked	 into	human	 intestinal	
organoids	using	CRISPR/Cas9	genome	editing	[314].	This	would	enable	selective	scRNA-seq	





This	 thesis	 has	 expanded	 the	 current	 comprehension	 of	 synergy	 between	 the	Gs	 and	Gq-
coupled	signalling	pathways	in	L-cells	and	colonic	enteroendocrine	cell	diversity.	It	is	hoped	
that	by	pharmacologically	replicating	the	synergistic	effects	of	GPBAR-1	activation	on	FFAR1-
mediated	GLP-1	 secretion	 new	 type	 2	 diabetes	 treatments	 could	 be	 developed.	 Similarly,	
pharmacological	 exploitation	 of	 identified	 differences	 between	 enteroendocrine	 cell	
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Ensembl	ID		 Gene	 Protein	Product	
ENSMUSG00000000194	 Gpr107	 G	Protein-Coupled	Receptor	107	
ENSMUSG00000000562	 Adora3	 Adenosine	A3	Receptor	
ENSMUSG00000001761	 Smo	 Smoothened,	Frizzled	Class	Receptor	
ENSMUSG00000002871	 Tpra1	 Transmembrane	Protein,	Adipocyte	Asscociated	1	
ENSMUSG00000002885	 Adgre5	 Adhesion	G	Protein-Coupled	Receptor	E5	
ENSMUSG00000004730	 Adgre1	 Adhesion	G	Protein-Coupled	Receptor	E1	
ENSMUSG00000005823	 Gpr108	 G	Protein-Coupled	Receptor	108	
ENSMUSG00000007989	 Fzd3	 Frizzled	Class	Receptor	3	
ENSMUSG00000008734	 Gprc5b	 G	Protein-Coupled	Receptor,	Class	C,	Group	5,	Member	B	
ENSMUSG00000011171	 Vipr2	 Vasoactive	Intestinal	Peptide	Receptor	2	
ENSMUSG00000013033	 Adgrl1	 Adhesion	G	Protein-Coupled	Receptor	L1	
ENSMUSG00000016028	 Celsr1	 Cadherin,	Egf	Lag	Seven-Pass	G-Type	Receptor	1	
ENSMUSG00000018500	 Adora2b	 Adenosine	A2B	Receptor	
ENSMUSG00000019429	 Ffar3	 Free	Fatty	Acid	Receptor	3	
ENSMUSG00000019464	 Ptger1	 Prostaglandin	E	Receptor	1	(Subtype	Ep1),	42Kda	
ENSMUSG00000019828	 Grm1	 Glutamate	Receptor,	Metabotropic	1	
ENSMUSG00000019905	 Gprc6a	 G	Protein-Coupled	Receptor,	Class	C,	Group	6,	Member	A	
ENSMUSG00000020090	 Npffr1	 Neuropeptide	Ff	Receptor	1	
ENSMUSG00000020123	 Avpr1a	 Arginine	Vasopressin	Receptor	1A	
ENSMUSG00000020178	 Adora2a	 Adenosine	A2A	Receptor	
ENSMUSG00000020793	 Galr2	 Galanin	Receptor	2	
ENSMUSG00000020963	 Tshr	 Thyroid	Stimulating	Hormone	Receptor	
ENSMUSG00000021298	 Gpr132	 G	Protein-Coupled	Receptor	132	
ENSMUSG00000021678	 F2rl1	 Coagulation	Factor	Ii	(Thrombin)	Receptor-Like	1	
ENSMUSG00000021886	 Gpr65	 G	Protein-Coupled	Receptor	65	
ENSMUSG00000022122	 Ednrb	 Endothelin	Receptor	Type	B	
ENSMUSG00000022297	 Fzd6	 Frizzled	Class	Receptor	6	
ENSMUSG00000022755	 Adgrg7	 Adhesion	G	Protein-Coupled	Receptor	G7	
ENSMUSG00000023473	 Celsr3	 Cadherin,	Egf	Lag	Seven-Pass	G-Type	Receptor	3	
ENSMUSG00000024027	 Glp1r	 Glucagon-Like	Peptide	1	Receptor	
ENSMUSG00000024462	 Gabbr1	 Gamma-Aminobutyric	Acid	(Gaba)	B	Receptor,	1	
ENSMUSG00000024553	 Galr1	 Galanin	Receptor	1	
ENSMUSG00000025127	 Gcgr	 Glucagon	Receptor	
ENSMUSG00000025496	 Drd4	 Dopamine	Receptor	D4	
ENSMUSG00000025804	 Ccr1	 Chemokine	(C-C	Motif)	Receptor	1	
ENSMUSG00000025905	 Oprk1	 Opioid	Receptor,	Kappa	1	
ENSMUSG00000026180	 Cxcr2	 Chemokine	(C-X-C	Motif)	Receptor	2	
ENSMUSG00000026237	 Nmur1	 Neuromedin	U	Receptor	1	
ENSMUSG00000026271	 Gpr35	 G	Protein-Coupled	Receptor	35	
ENSMUSG00000026322	 Htr4	 5-Hydroxytryptamine	(Serotonin)	Receptor	4,	G	Protein-Coupled	
ENSMUSG00000026343	 Gpr39	 G	Protein-Coupled	Receptor	39	
ENSMUSG00000026424	 Gpr37l1	 G	Protein-Coupled	Receptor	37	Like	1	
ENSMUSG00000026432	 Avpr1b	 Arginine	Vasopressin	Receptor	1B	
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ENSMUSG00000026469	 Xpr1	 Xenotropic	And	Polytropic	Retrovirus	Receptor	1	
ENSMUSG00000026525	 Opn3	 Opsin	3	
ENSMUSG00000027584	 Oprl1	 Opiate	Receptor-Like	1	
ENSMUSG00000027762	 Sucnr1	 Succinate	Receptor	1	
ENSMUSG00000027765	 P2ry1	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	1	
ENSMUSG00000028004	 Npy2r	 Neuropeptide	Y	Receptor	Y2	
ENSMUSG00000028012	 Rrh	 Retinal	Pigment	Epithelium-Derived	Rhodopsin	Homolog	
ENSMUSG00000028172	 Tacr3	 Tachykinin	Receptor	3	
ENSMUSG00000028184	 Adgrl2	 Adhesion	G	Protein-Coupled	Receptor	L2	
ENSMUSG00000028738	 Tas1r2	 Taste	Receptor,	Type	1,	Member	2	
ENSMUSG00000028950	 Tas1r1	 Taste	Receptor,	Type	1,	Member	1	
ENSMUSG00000029072	 Tas1r3	 Taste	Receptor,	Type	1,	Member	3	
ENSMUSG00000029090	 Adgra3	 Adhesion	G	Protein-Coupled	Receptor	A3	
ENSMUSG00000029193	 Cckar	 Cholecystokinin	A	Receptor	
ENSMUSG00000029530	 Ccr9	 Chemokine	(C-C	Motif)	Receptor	9	
ENSMUSG00000029778	 Adcyap1r1	 Adenylate	Cyclase	Activating	Polypeptide	1	(Pituitary)	Receptor	Type	I	
ENSMUSG00000030324	 Rho	 Rhodopsin	
ENSMUSG00000030406	 Gipr	 Gastric	Inhibitory	Polypeptide	Receptor	
ENSMUSG00000031070	 Mrgprf	 Mas-Related	Gpr,	Member	F	
ENSMUSG00000031210	 Gpr165	 G	Protein-Coupled	Receptor	165	
ENSMUSG00000031298	 Adgrg2	 Adhesion	G	Protein-Coupled	Receptor	G2	
ENSMUSG00000031364	 Grpr	 Gastrin-Releasing	Peptide	Receptor	
ENSMUSG00000031390	 Avpr2	 Arginine	Vasopressin	Receptor	2	
ENSMUSG00000031486	 Adgra2	 Adhesion	G	Protein-Coupled	Receptor	A2	
ENSMUSG00000031785	 Adgrg1	 Adhesion	G	Protein-Coupled	Receptor	G1	
ENSMUSG00000031861	 Lpar2	 Lysophosphatidic	Acid	Receptor	2	
ENSMUSG00000031932	 Gpr83	 G	Protein-Coupled	Receptor	83	
ENSMUSG00000032259	 Drd2	 Dopamine	Receptor	D2	
ENSMUSG00000032492	 Pth1r	 Parathyroid	Hormone	1	Receptor	
ENSMUSG00000032528	 Vipr1	 Vasoactive	Intestinal	Peptide	Receptor	1	
ENSMUSG00000032641	 Gpr19	 G	Protein-Coupled	Receptor	19	
ENSMUSG00000032773	 Chrm1	 Cholinergic	Receptor,	Muscarinic	1	
ENSMUSG00000032860	 P2ry2	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	2	
ENSMUSG00000033446	 Lpar6	 Lysophosphatidic	Acid	Receptor	6	
ENSMUSG00000033470	 Cysltr2	 Cysteinyl	Leukotriene	Receptor	2	
ENSMUSG00000033569	 Adgrb3	 Adhesion	G	Protein-Coupled	Receptor	B3	
ENSMUSG00000033717	 Adra2a	 Adrenoceptor	Alpha	2A	
ENSMUSG00000034677	 Gpr142	 G	Protein-Coupled	Receptor	142	
ENSMUSG00000034881	 Tbxa2r	 Thromboxane	A2	Receptor	
ENSMUSG00000034987	 Hrh2	 Histamine	Receptor	H2	
ENSMUSG00000035431	 Sstr1	 Somatostatin	Receptor	1	
ENSMUSG00000035773	 Kiss1r	 Kiss1	Receptor	
ENSMUSG00000036362	 P2ry13	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	13	
ENSMUSG00000036381	 P2ry14	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	14	
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ENSMUSG00000036437	 Npy1r	 Neuropeptide	Y	Receptor	Y1	
ENSMUSG00000036904	 Fzd8	 Frizzled	Class	Receptor	8	
ENSMUSG00000037605	 Adgrl3	 Adhesion	G	Protein-Coupled	Receptor	L3	
ENSMUSG00000037661	 Gpr160	 G	Protein-Coupled	Receptor	160	
ENSMUSG00000037759	 Ptger2	 Prostaglandin	E	Receptor	2	(Subtype	Ep2),	53Kda	
ENSMUSG00000038390	 Gpr162	 G	Protein-Coupled	Receptor	162	
ENSMUSG00000038668	 Lpar1	 Lysophosphatidic	Acid	Receptor	1	
ENSMUSG00000039059	 Hrh3	 Histamine	Receptor	H3	
ENSMUSG00000039167	 Adgrl4	 Adhesion	G	Protein-Coupled	Receptor	L4	
ENSMUSG00000039809	 Gabbr2	 Gamma-Aminobutyric	Acid	(Gaba)	B	Receptor,	2	
ENSMUSG00000039904	 Gpr37	 G	Protein-Coupled	Receptor	37	(Endothelin	Receptor	Type	B-Like)	
ENSMUSG00000039942	 Ptger4	 Prostaglandin	E	Receptor	4	(Subtype	Ep4)	
ENSMUSG00000040016	 Ptger3	 Prostaglandin	E	Receptor	3	(Subtype	Ep3)	
ENSMUSG00000040229	 Gpr34	 G	Protein-Coupled	Receptor	34	
ENSMUSG00000040432	 Ltb4r2	 Leukotriene	B4	Receptor	2	
ENSMUSG00000040495	 Chrm4	 Cholinergic	Receptor,	Muscarinic	4	
ENSMUSG00000040836	 Gpr161	 G	Protein-Coupled	Receptor	161	
ENSMUSG00000041075	 Fzd7	 Frizzled	Class	Receptor	7	
ENSMUSG00000041293	 Adgrf1	 Adhesion	G	Protein-Coupled	Receptor	F1	
ENSMUSG00000041347	 Bdkrb1	 Bradykinin	Receptor	B1	
ENSMUSG00000041468	 Gpr12	 G	Protein-Coupled	Receptor	12	
ENSMUSG00000041762	 Gpr155	 G	Protein-Coupled	Receptor	155	
ENSMUSG00000041907	 Gpr45	 G	Protein-Coupled	Receptor	45	
ENSMUSG00000042262	 Ccr8	 Chemokine	(C-C	Motif)	Receptor	8	
ENSMUSG00000042429	 Adora1	 Adenosine	A1	Receptor	
ENSMUSG00000042804	 Gpr153	 G	Protein-Coupled	Receptor	153	
ENSMUSG00000043366	 Olfr78	 Olfactory	Receptor,	Family	51,	Subfamily	E,	Member	2	
ENSMUSG00000043398	 Gpr135	 G	Protein-Coupled	Receptor	135	
ENSMUSG00000043880	 Olfr323	 Olfactory	Receptor,	Family	11,	Subfamily	L,	Member	1	
ENSMUSG00000043895	 S1pr2	 Sphingosine-1-Phosphate	Receptor	2	
ENSMUSG00000043953	 Ccrl2	 Chemokine	(C-C	Motif)	Receptor-Like	2	
ENSMUSG00000043999	 Gpr75	 G	Protein-Coupled	Receptor	75	
ENSMUSG00000044017	 Adgrd1	 Adhesion	G	Protein-Coupled	Receptor	D1	
ENSMUSG00000044052	 Ccr10	 Chemokine	(C-C	Motif)	Receptor	10	
ENSMUSG00000044067	 Gpr22	 G	Protein-Coupled	Receptor	22	
ENSMUSG00000044199	 S1pr4	 Sphingosine-1-Phosphate	Receptor	4	
ENSMUSG00000044288	 Cnr1	 Cannabinoid	Receptor	1	(Brain)	
ENSMUSG00000044337	 Ackr3	 Atypical	Chemokine	Receptor	3	
ENSMUSG00000044338	 Aplnr	 Apelin	Receptor	
ENSMUSG00000044359	 P2ry4	 Pyrimidinergic	Receptor	P2Y,	G-Protein	Coupled,	4	
ENSMUSG00000044453	 Ffar1	 Free	Fatty	Acid	Receptor	1	
ENSMUSG00000044674	 Fzd1	 Frizzled	Class	Receptor	1	
ENSMUSG00000044819	 Oxgr1	 Oxoglutarate	(Alpha-Ketoglutarate)	Receptor	1	
ENSMUSG00000044933	 Sstr3	 Somatostatin	Receptor	3	
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ENSMUSG00000045005	 Fzd5	 Frizzled	Class	Receptor	5	
ENSMUSG00000045092	 S1pr1	 Sphingosine-1-Phosphate	Receptor	1	
ENSMUSG00000045267	 Tas2r119	 Taste	Receptor,	Type	2,	Member	1	
ENSMUSG00000045281	 Gpr20	 G	Protein-Coupled	Receptor	20	
ENSMUSG00000045382	 Cxcr4	 Chemokine	(C-X-C	Motif)	Receptor	4	
ENSMUSG00000045502	 Hcar2	 Hydroxycarboxylic	Acid	Receptor	2	
ENSMUSG00000045509	 Gpr150	 G	Protein-Coupled	Receptor	150	
ENSMUSG00000045730	 Adrb2	 Adrenoceptor	Beta	2,	Surface	
ENSMUSG00000045824	 Olfr574	 Olfactory	Receptor,	Family	51,	Subfamily	T,	Member	1	
ENSMUSG00000045967	 Gpr158	 G	Protein-Coupled	Receptor	158	
ENSMUSG00000046159	 Chrm3	 Cholinergic	Receptor,	Muscarinic	3	
ENSMUSG00000046733	 Gprc5a	 G	Protein-Coupled	Receptor,	Class	C,	Group	5,	Member	A	
ENSMUSG00000046856	 Gpr1	 G	Protein-Coupled	Receptor	1	
ENSMUSG00000046908	 Ltb4r1	 Leukotriene	B4	Receptor	
ENSMUSG00000046922	 Gpr6	 G	Protein-Coupled	Receptor	6	
ENSMUSG00000046985	 Tapt1	 Transmembrane	Anterior	Posterior	Transformation	1	
ENSMUSG00000047259	 Mc4r	 Melanocortin	4	Receptor	
ENSMUSG00000047415	 Gpr68	 G	Protein-Coupled	Receptor	68	
ENSMUSG00000047875	 Gpr157	 G	Protein-Coupled	Receptor	157	
ENSMUSG00000047904	 Sstr2	 Somatostatin	Receptor	2	
ENSMUSG00000048216	 Gpr85	 G	Protein-Coupled	Receptor	85	
ENSMUSG00000048337	 Npy4r	 Neuropeptide	Y	Receptor	Y4	
ENSMUSG00000048376	 F2r	 Coagulation	Factor	Ii	(Thrombin)	Receptor	
ENSMUSG00000048521	 Cxcr6	 Chemokine	(C-X-C	Motif)	Receptor	6	
ENSMUSG00000048779	 P2ry6	 Pyrimidinergic	Receptor	P2Y,	G-Protein	Coupled,	6	
ENSMUSG00000048965	 Mrgpre	 Mas-Related	Gpr,	Member	E	
ENSMUSG00000049103	 Ccr2	 Chemokine	(C-C	Motif)	Receptor	2	
ENSMUSG00000049112	 Oxtr	 Oxytocin	Receptor	
ENSMUSG00000049115	 Agtr1a	 Angiotensin	Ii	Receptor,	Type	1	
ENSMUSG00000049130	 C5ar1	 Complement	Component	5A	Receptor	1	
ENSMUSG00000049241	 Hcar1	 Hydroxycarboxylic	Acid	Receptor	1	
ENSMUSG00000049511	 Htr1b	 5-Hydroxytryptamine	(Serotonin)	Receptor	1B,	G	Protein-Coupled	
ENSMUSG00000049551	 Fzd9	 Frizzled	Class	Receptor	9	
ENSMUSG00000049608	 Gpr55	 G	Protein-Coupled	Receptor	55	
ENSMUSG00000049649	 Gpr3	 G	Protein-Coupled	Receptor	3	
ENSMUSG00000049741	 Rxfp4	 Relaxin/Insulin-Like	Family	Peptide	Receptor	4	
ENSMUSG00000049791	 Fzd4	 Frizzled	Class	Receptor	4	
ENSMUSG00000050075	 Gpr171	 G	Protein-Coupled	Receptor	171	
ENSMUSG00000050147	 F2rl3	 Coagulation	Factor	Ii	(Thrombin)	Receptor-Like	3	
ENSMUSG00000050158	 Olfr165	 Olfactory	Receptor,	Family	2,	Subfamily	M,	Member	5	
ENSMUSG00000050164	 Mchr1	 Melanin-Concentrating	Hormone	Receptor	1	
ENSMUSG00000050232	 Cxcr3	 Chemokine	(C-X-C	Motif)	Receptor	3	
ENSMUSG00000050288	 Fzd2	 Frizzled	Class	Receptor	2	
ENSMUSG00000050350	 Gpr18	 G	Protein-Coupled	Receptor	18	
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ENSMUSG00000050511	 Oprd1	 Opioid	Receptor,	Delta	1	
ENSMUSG00000050534	 Htr5b	 5-Hydroxytryptamine	(Serotonin)	Receptor	5B	
ENSMUSG00000050541	 Adra1b	 Adrenoceptor	Alpha	1B	
ENSMUSG00000050824	 Sstr5	 Somatostatin	Receptor	5	
ENSMUSG00000050921	 P2ry10	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	10	
ENSMUSG00000051043	 Gprc5c	 G	Protein-Coupled	Receptor,	Class	C,	Group	5,	Member	C	
ENSMUSG00000051182	 Olfr655	 Olfactory	Receptor	655	
ENSMUSG00000051209	 Gpr119	 G	Protein-Coupled	Receptor	119	
ENSMUSG00000051314	 Ffar2	 Free	Fatty	Acid	Receptor	2	
ENSMUSG00000051980	 Casr	 Calcium-Sensing	Receptor	
ENSMUSG00000052336	 Cx3cr1	 Chemokine	(C-X3-C	Motif)	Receptor	1	
ENSMUSG00000052821	 Cysltr1	 Cysteinyl	Leukotriene	Receptor	1	
ENSMUSG00000053004	 Hrh1	 Histamine	Receptor	H1	
ENSMUSG00000053164	 Gpr21	 G	Protein-Coupled	Receptor	21	
ENSMUSG00000053251	 Olfr212	 Olfactory	Receptor	212	
ENSMUSG00000053368	 Rxfp2	 Relaxin/Insulin-Like	Family	Peptide	Receptor	2	
ENSMUSG00000053647	 Gper1	 G	Protein-Coupled	Estrogen	Receptor	1	
ENSMUSG00000054200	 Ffar4	 Free	Fatty	Acid	Receptor	4	
ENSMUSG00000054764	 Mtnr1a	 Melatonin	Receptor	1A	
ENSMUSG00000054988	 Agtr1b	 Angiotensin	Ii	Receptor,	Type	1B	
ENSMUSG00000056492	 Adgrf5	 Adhesion	G	Protein-Coupled	Receptor	F5	
ENSMUSG00000056529	 Ptafr	 Platelet-Activating	Factor	Receptor	
ENSMUSG00000056679	 Gpr173	 G	Protein-Coupled	Receptor	173	
ENSMUSG00000058396	 Gpr182	 G	Protein-Coupled	Receptor	182	
ENSMUSG00000059588	 Calcrl	 Calcitonin	Receptor-Like	
ENSMUSG00000059867	 Olfr960	 Olfactory	Receptor	960	
ENSMUSG00000060470	 Adgrg3	 Adhesion	G	Protein-Coupled	Receptor	G3	
ENSMUSG00000060509	 Xcr1	 Chemokine	(C	Motif)	Receptor	1	
ENSMUSG00000061039	 Olfr920	 Olfactory	Receptor	920	
ENSMUSG00000061577	 Adgrg5	 Adhesion	G	Protein-Coupled	Receptor	G5	
ENSMUSG00000061972	 Olfr99	 Olfactory	Receptor	99	
ENSMUSG00000062585	 Cnr2	 Cannabinoid	Receptor	2	(Macrophage)	
ENSMUSG00000062905	 Vmn1r32	 Vomeronasal	1	Receptor	32	
ENSMUSG00000063239	 Grm4	 Glutamate	Receptor,	Metabotropic	4	
ENSMUSG00000064272	 Gpbar1	 G	Protein-Coupled	Bile	Acid	Receptor	1	
ENSMUSG00000067586	 S1pr3	 Sphingosine-1-Phosphate	Receptor	3	
ENSMUSG00000067714	 Lpar5	 Lysophosphatidic	Acid	Receptor	5	
ENSMUSG00000068740	 Celsr2	 Cadherin,	Egf	Lag	Seven-Pass	G-Type	Receptor	2	
ENSMUSG00000069170	 Adgrv1	 Adhesion	G	Protein-Coupled	Receptor	V1	
ENSMUSG00000070337	 Gpr179	 G	Protein-Coupled	Receptor	179	
ENSMUSG00000070423	 Olfr558	 Olfactory	Receptor,	Family	51,	Subfamily	E,	Member	1	
ENSMUSG00000070687	 Htr1d	 5-Hydroxytryptamine	(Serotonin)	Receptor	1D,	G	Protein-Coupled	
ENSMUSG00000071489	 Ptgdr	 Prostaglandin	D2	Receptor	(Dp)	
ENSMUSG00000071893	 Vmn1r4	 Vomeronasal	1	Receptor	4	
	 186	
ENSMUSG00000072875	 Gpr27	 G	Protein-Coupled	Receptor	27	
ENSMUSG00000073964	 Olfr570	 Olfactory	Receptor	570	
ENSMUSG00000073966	 Olfr561	 Olfactory	Receptor	561	
ENSMUSG00000074037	 Mc1r	 Melanocortin	1	Receptor	(⍺-MSH	Receptor)	
ENSMUSG00000074361	 C5ar2	 Complement	Component	5A	Receptor	2	
ENSMUSG00000078698	 Mrgpra3	 Mas-Related	Gpr,	Member	A3	
ENSMUSG00000079227	 Ccr5	 Chemokine	(C-C	Motif)	Receptor	5	(Gene/Pseudogene)	
ENSMUSG00000079355	 Ackr4	 Atypical	Chemokine	Receptor	4	
ENSMUSG00000081683	 Fzd10	 Frizzled	Class	Receptor	10	
ENSMUSG00000091735	 Gpr62	 G	Protein-Coupled	Receptor	62	
ENSMUSG00000094295	 Olfr819	 Olfactory	Receptor	247	
ENSMUSG00000095730	 Vmn2r29	 Vomeronasal	2,	Receptor	32	
	
Appendix	3:	Table	of	annotated	GPCR	genes	examined	in	the	differential	expression	analysis.	
	
	
